1
Status: Approved ,  Date: 5 October 2017Janssen Research & Development*
Clinical Protocol
A Phase 3, Multicenter, Randomized, Double- blind Study Evaluating the Comparative 
Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to 
Severe Plaque -type Psoriasis
ECLIPSE
Protocol CNTO1959PSO3009; Phase 3
AMENDMENT 1
CNTO 1959 (guselkumab)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, I nc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entitie s; the sponsor is identified on the Contact [CONTACT_170456].
This study  will be conducted under US Food & Drug Administration I ND regulations 
(21 CFR Part 312).
EudraCT NUMBER: 2016 -002995 -29
Status: Approved
Date: 5 October 2017
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number : EDMS- ERI-128153718
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, per sons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is in dicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
2
Approved , Date: [ADDRESS_1203899] POPUL ATION.................................................................................................................. 26
4.1. Inclusion Criteria ............................................................................................................................ 26
4.2. Exclusion Criteria ........................................................................................................................... 29
4.3. Prohibitions and Restrictions ......................................................................................................... 33
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 34
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 35
7. TREA TMENT COMPLIA NCE ............................................................................................................ 36
8. CONCOMIT ANT THERA PY.............................................................................................................. 36
8.1.1. Concomitant Medications for Treatment of Psoriasis ................................................................ .36
[IP_ADDRESS]. Topi[INVESTIGATOR_160794] ....................................................................................................................... 36
[IP_ADDRESS]. Phototherapy or Systemic The rapy for Psoriasis .................................................................... 37
8.1.2. Concomitant Medications for Conditions Other than Psoriasis .................................................. 37
9. STUDY EVA LUATIONS .................................................................................................................... 37
9.1. Study Procedures ........................................................................................................................... 37
9.1.1. Overview ..................................................................................................................................... 37
9.1.2. Screening Phase ........................................................................................................................ 38
9.1.3. Screen Failure/Rescreening ....................................................................................................... 39
9.1.4. Double -Blind Treatment Phase .................................................................................................. 39
9.1.5. Posttreatment Phase (Follow -Up).............................................................................................. 40
9.2. Efficacy  Evaluations ....................................................................................................................... 40
9.2.1. Evaluations ................................................................................................................................ .40
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
3
Approved , Date: 5 October [ZIP_CODE].2.1.1. Investigator’s Global Assessment ........................................................................................... 40
[IP_ADDRESS]. Psoriasis Area and Severity Index .......................................................................................... 40
9.3. Pharmacokinetics and Immunogenicity ......................................................................................... 41
9.4. Biom arkers ..................................................................................................................................... 41
9.5. Genetic (DNA) Analysis ................................................................................................................. [ADDRESS_1203900] COMPLETION/D ISCONTINUA TION OF ST UDY TREA TMENT/ WITHDR AWAL 
FROM THE STUDY ........................................................................................................................... 48
10.1. Completion ..................................................................................................................................... 48
10.2. Discontinuation of Study Treatment/ Withdrawal from the Study ................................................... [ADDRESS_1203901] Information ........................................................................................................................ 52
11.2. Sample Size Determination ........................................................................................................... 52
11.3. Efficacy  Analyses ........................................................................................................................... 53
11.3.1. Analysis Data Set ....................................................................................................................... 53
11.3.2. Primary Analy sis......................................................................................................................... 53
11.3.3. Major Secondary Analy ses......................................................................................................... 54
[IP_ADDRESS]. Multiplicity Control ................................................................................................................... [ADDRESS_1203902] Quality ............................................................................ 64
14. STUDY DRUG INFORM ATION......................................................................................................... 64
14.1. Physical Description of Study Drug(s) ........................................................................................... 64
14.1.1. Guselkumab ................................................................................................................................ 64
14.1.2. Cosenty x (Secukinumab) ............................................................................................................ 65
14.2. Packaging ...................................................................................................................................... 65
14.3. Labeling .......................................................................................................................................... 65
14.4. Preparation, Handling, and Storage ............................................................................................... 65
14.4.1. Guselkumab ................................................................................................................................ 65
14.4.2. Cosenty x (Secukinumab) ............................................................................................................ 65
14.5. Drug Accountability ........................................................................................................................ 66
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
4
Approved , Date: [ADDRESS_1203903] ................................................... 67
16.2.3. Informed Consent ....................................................................................................................... 69
16.2.4. Privacy of Personal Data ............................................................................................................ 70
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 70
16.2.6. Countr y Selection ....................................................................................................................... 71
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 71
17.1. Protocol Amendments .................................................................................................................... 71
17.2. Regulatory Documentation ............................................................................................................ 71
17.2.1. Regulatory Approval/Notification ................................................................................................ [ADDRESS_1203904] Identification, Enrollment, and Screening Logs ................................................................ 72
17.4. Source Do cumentation ................................................................................................................... 73
17.5. Case Report Form Completion ...................................................................................................... 73
17.6. Data Quality Assurance/Quality Control ........................................................................................ [ADDRESS_1203905] Retention ........................................................................................................................... 74
17.8. Monitoring ...................................................................................................................................... 75
17.9. Study Com pletion/Termination ....................................................................................................... 75
17.9.1. Study Com pletion/End of Study .................................................................................................. [ADDRESS_1203906] OF A TTACHMENTS
Attachment 1: Inves tigator’s Global Assessment .............................................................................. 79
Attachment 2: Psoriasis Area and Severity Index ............................................................................. 80
Attachment 3: QuantiFERON®-TB Gold Testing ............................................................................... 81
Attachment 4: Tuberculin Skin Testing .............................................................................................. 83
Attachment 5: Hepatitis B Virus (HBV) Screening W ith HBV DNA Testing ....................................... 84
Attachment 6: Anticipated Events ...................................................................................................... [ADDRESS_1203907] OF IN-TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Power to Detect a Treatment Effect Based on Different Proportions of Subjects 
Achieving the Primary Endpoint PASI 90 at W eek 48 and the Major Secondary 
Endpoint PASI 100 at W eek48................................................................................................ 53
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 24
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
5
Approved , Date: [ADDRESS_1203908] recent amendment.
Amendment 1 (5 October 2017)
This amendm ent is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union , in that it does not significantly 
impact the safety or physical/mental integrity of subjects, nor the scientific v alue of the study.
The overall reason for the amendment: The overall reason for the amendment is to delete thereference to the 
Week 48 database lock (DBL) as detailed in the original study design.   The study will have a singular database lock
(DBL) at Week 56.
Applicable Section(s) Description of Change(s)
Rationale: To delete the reference to the database lock (DBL) at Week 48 from the Study Design, and clarify that 
only one database lock (DBL) will occur at Week 56.
Synopsis ,Overview 
ofStudy Design;
3.1. Overview  of 
Study Design, After 
Week 44 through 
Week 56 (Follow -up 
Period)There are [ADDRESS_1203909] has completed the Week 48 visit and the Week 48 DBL 
has occurred. The sponsor, theinvestigators and subjects will be unblinded after the 
Week 56 DBL has occurred.
Figure 1: Schematic 
Overvie w of the StudyThe reference to the DBL at Week 48 has been deleted from the study schematic 
timeline.
Rationale: To clarify that subjects who complete their final study visit prior to Week [ADDRESS_1203910] blood 
samples drawn for analysis of serum biomarkers.
Time and Events 
Schedule
Footnote b and j.b:  All Week [ADDRESS_1203911] who terminates 
the study prior to Week 48 , except for collection of serum  for biom arkers .
j: Serum biom arker measurements will include but are not limited to: serum IL-17A, 
IL-17F, and IL-22. For subjects who discontinue from the study prior to 
Week 48, serum is not to be collected for m easurement of biomarkers.
10.2 Discontinuation 
of Study 
Treatment/Withdrawal 
from the StudyDiscontinuation of Study Treatm ent[last paragraph]
If thesubject discontinues study treatment before his or her last scheduled injection, he 
or she should return for the remaining regularly scheduled study visits for at least [ADDRESS_1203912] the 
Week 48 assessments as indicated in the Time and Events Schedule. For subjects who 
discontinue from the study prior to Week 48, serum is not to be collected for 
measurement of biom arkers.
Rationale: To correct Exclusion Criterion #23 to specify that Exclusion Criterion #24 and not#28 applies to 
BCG vaccination.
4.2.Exclusion Criteria
Criterion #2323. Has received, or is expected to receive, any live virus or bacterial vaccination 
within [ADDRESS_1203913] administration of study drug. For BCG vaccine, 
see Exclusion Criterion 2824.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
6
Approved , Date: 5 October 2017Applicable Section(s) Description of Change(s)
Rationale: To clarify the subject study visits at which each version of the Electronic Columbia -Suicide Severity 
Rating Scale (eC -SSRS) is to be conducted.
9.6.1. Electronic 
Columbia -Suicide 
Severity Rating ScaleThe ‘Baseline/Screening’ version of the eC-SSRS will be conducted during the 
screening visit followed by [CONTACT_941] ‘Since Last Visit’ version of the eC-SSRS at Week 0, 
andall visits from baseline/Week 0starting at Week 4 through Week 56.
Rationale: To replace X -ray with ECG Manual since an x-ray manual was not provided to the sites.
15. Study -Specific 
MaterialsX-rayECG Manual.
Rationale: Minor errors w ere noted.
Throughout the 
protocol.Minor grammatical, formatting, o r spelling changes were made.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
7
Approved , Date: 5 October 2017SYNOPSIS
A Phase 3, Multicenter, Randomized, Double- blind Study Evaluating the Comparative Efficacy of 
CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque -type 
Psoriasis
Protocol Number: CNTO1959PSO3009
OBJECTIVES, ENDPOINTS, AND HYPOTHESES
Primary Objective
The primary objective is to evaluate the efficacy of guselkumab compared with secukinumab for the 
treatment of subjects with moderate to severe plaque -type psoriasis.
Secondary Objective
The secondary objectives are to assess:
 The safety and tolerability of guselkumab in subjects with moderate to severe plaque -type psoriasis.
 The PK and immunogenicity of guselkumab after subcutaneous (SC) administrations in subjects with 
moderate to severe plaque -type psoriasis.
Primary Endpoint
The primary endpoint in this study is the proportion of subjects who achieve a Psoriasis Area and Severity 
Index (PASI )90 response at Week 48, comparing the guselkumab group and the secukinumab group.
Major Secondary Endpoints
The major secondary endpoints to compare the guselkumab group and the secukinumab group are listed 
below and are the proportion of subjects who achieve:
 A PASI 75 response at both Week 12 and Week 48 .
 APASI 90response at Week 12.
 APASI 75response at We ek 12.
 A PASI 100 response at Week 48 .
 An In vestigator’s Global Assessment (IGA)score of cleared (0) at Week 48.
Other Secondary Endpoints
 The other secondary endpoints to compare the guselkumab group and the secukinumab group are 
listed below and are the proportion of subjects who achieve:
 A PASI 90 response at both Week 16 and Week 48 .
 A PASI 75 response at Week 16 .
 A PASI 90 response at Week 16 .
 A PASI 90 response at all 7 visits from Week 24 through Week 48 .
 An IGA score of cleared (0) or minimal (1) a t Week 16 .
 An IGA score of cleared (0) or minimal (1) at Week 12 .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
8
Approved , Date: 5 October 2017 The proportions of subjects who achieve a PASI 75 response at Week 48 among PASI 75 responders 
at Week 12.
 The proportions of subjects who achieve a PASI 90 response at Week 48 among PASI 90 responders 
at Week 16.
 The proportions of subjects who achieve a PASI 50/75/90/100 response over time through Week 48.
 The proportions of subjects who achieve an IGA score of cleared (0) response, IGA score of cleared 
(0) or minimal (1) response, and IGA of cleared (0), minimal (1), or mild (2)response over time 
through Week 48.
 Percentages of improvement from baseline in PASI over time through Week 48.
Hypotheses
The proposed randomized, blinded, two- active -arm trial will evaluate the relative performance of 
guselkumab and secukinumab utilizing a comprehensive battery of endpoints (eg, PASI 75, 90, and 100) 
at various timepoints (eg, Week 12 and Week 48) using rigorous statistical methodology to control for 
multiplicity.
While the ultimate goal of the trial is to demonstrate that the efficacy of guselkumab is superior to 
secukinumab for PASI [ADDRESS_1203914] for non-inferiority isincluded for this endpoint 
because the overall profile of guselkumab will likely be favorable compared with secukinumab (in terms 
of potential for increased compliance and lesser patient burden) ,even if final results only indicate the 
relative efficacy i s no worse for this endpoint .
The primary hypotheses are that guselkumab treatment is non-inferior to secukinumab as assessed by [CONTACT_863353] a PASI 90 response at Week 48with a non-inferiority margin of 10%
and, once non-inferiori ty is established, that guselkumab is superior to secukinumab as assessed by [CONTACT_863353] a PASI 90 response at Week 48.
The major secondary hypotheses are that guselkumab treatment is:
 Non-inferior to secukinumab for the maintenanc e of a PASI 75 response as assessed by [CONTACT_863354] a PASI 75 response at both Week 12 and Week 48 with a non-
inferiority margin of 10% and, once non-inferiority is established, that guselkumab is superior to 
secukinumab as assess ed by [CONTACT_863355] a PASI 75 response at both 
Week 12 and Week 48 .
 Non-inferior to secukinumab at Week 12 as assessed by [CONTACT_863356] 90 at Week 12 with a non- inferiority margin of 10% .
 Non-inferior to secukinumab at Week 12 as assessed by [CONTACT_863356] 75 at Week 12 with a non- inferiority margin of 10% .
 Non-inferior to secukinumab at Week 48 as assessed by [CONTACT_863356] 100 at Week 48 with a non-inferiority margin of 10% and, once non-inferiority is established, 
that guselkumab is superior to secukinumab as assessed by [CONTACT_863355] a 
PASI 100 response at Week 48.
 Non-inferior to secukinumab at Week 48 as assessed by [CONTACT_863357] (0) at Week 48 with a non-inferiority margin of 10% and, once non-inferiority 
is established, that guselkumab is superior to secukinumab as assessed by [CONTACT_863358] (0) at Week 48 .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
9
Approved , Date: 5 October 2017OVERVIEW OF STUDY DESIGN
This is a Phase 3, randomized, double -blind, multicenter, active -controlled study evaluating the 
comparative efficacy of CNTO 1959 (guselkumab) and secukinumab in subjects with moderate to severe 
plaque -type psoriasis.
There is 1database lock (DBL) in this study at Week 56. The sponsor, the investigators and subjects will 
be unblinded after the Week [ADDRESS_1203915] POPULATION
The target population is adult men or women with a diagnosis of plaque -type psoriasis (with or without 
psoriatic arthritis) for at least [ADDRESS_1203916] 
moderate to severe plaque -type psoriasis defined by [CONTACT_47736] ≥12, IGA ≥3, and involved body surface 
area ≥10%. Subjects must be candidates for either systemic therapy or phototherapy for psoriasis, may 
have previously received some systemic therapi[INVESTIGATOR_863333], and be considered, in the 
opi[INVESTIGATOR_871], suitable candidates for secukinumab (Cosentyx®) therapy according to their 
country's approved secukinumab product labeling.
DOSAGE AND ADMINISTRATION
For those subjects random ized to guselkumab, a 100 mg/mL solution of guselkumab in a single -use 
prefilled syringe (PFS) assembled with the UltraSafe PLUS™ Passive Needle Guard (PFS -U) device will 
be used. Subjects who are randomized to the guselkumab treatment arm will receive 2 injections: 
1injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be 
administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is 
scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40), to mimic the secukinumab 300 mg 
dosing schedule consisting of 2 injections and to maintain the blind. For those subjects randomized to 
Cosentyx, commercially available secukinumab (Cosentyx) will be supplied as a single -use PFS and 
admini stered according to the manufacturer’s directions. Each 300mg dose is given as 2subcutaneous
injections of 150mg each. An appropriately qualified, unblinded member of the study staff will 
administer the drug and will have no other role in the conduct of the study .
All study drug injections will be administered at the investigational site. With the exception of the 
unblinded site personnel who dispense and/or administer the investigational product, all other site 
personnel and subjects will remain blinded to the treatment assignments until the last subject completes 
Week [ADDRESS_1203917] the ability to 
physically blind and/or separate the blinded subject from the unblinded administrator. A physical barrier 
must be used such that the study drug can be administered by [CONTACT_863359], and the subject 
and other site personnel remain blinded.
EFFICACY EVALUATIONS
Efficacy evaluations chosen for this study are consistent with those uti lized to evaluate other therapi[INVESTIGATOR_196254]. Efficacy evaluations include:
 IGA
 PASI
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
10
Approved , Date: 5 October 2017BIOMARKER EVALUATIONS
Biomarker sample collections will be conducted to measure serum markers, gene expression and cellular 
profiles in skin biopsies,  and genetic 
associations with psoriasis or response to treatment. Data collected from these samples will be used for 
exploratory research that will include the following objectives:
1. To understand the molecu lar effects of guselkumab and secukinumab.
2. To understand psoriasis pathogenesis.
3. To understand why individuals differ in their responses to guselkumab or secukinumab.
4.  
GENETIC (DNA) EVALUATIONS
Genetic (DNA) research may consist of the analysis of one or more candidate genes or analysis of the 
entire genome (as appropriate) in relation to guselkumab, secukinumab or psoriasis clinical endpoints. 
Whole blood samples will be collected for genetic analyses. Epi[INVESTIGATOR_863334]. Only subje ctswho sign the consent form to participate in 
the genetic (DNA) assessment will have whole blood DNA or skin samples collected.
SAFETY EVALUATIONS
Safety evaluations include assessments of the following: adverse events ( AEs; including injection -site and 
allergic reactions), clinical laborato ry tests (hematology, chemistry, and pregnancy testing), physical 
examinations, vital sign measurements, electrocardiograms, concomitant medication review, electronic 
Columbia -Suicide Severity Rating Scale (eC-SSRS) questionnaires ,and early detection of tuberculosis
(TB) .
STATISTICAL METHODS
Approximately 1,040 subjects will be randomized in a 1:1 ratio to guselkumab 100 mg (n=520) or 
secukinumab 300 mg (n=520) . With a non -inferiority margin of 10% and assumed treatment difference of 
[ADDRESS_1203918] > 99% power to demonstrate the non -inferiority for the primary 
endpoint of PASI [ADDRESS_1203919] 90% power to detect a trea tment difference (ie, superiority of 
guselkumab over secukinumab) for the primary endpoint of PASI [ADDRESS_1203920] the non-
inferiority of guselkumab to secukinumab , a 1-sided (α=0.025) Z-test with Mantel -Haenszel weights 
adjusted by [CONTACT_863360]. A longitudinal modeling approach will also be used as a 
sensitivity analysis to compare the proportion of subjects responding to treatment. All statistical testing 
will be performed 2 -sided at a significance level of 0.05 for superiority and 1 -sided at a significance level 
of 0.025 for non- inferiority.
Subjects who discontinue study agent due to lack of efficacy or an AEof worsening of psoriasis, or who 
started a protocol -prohibited medication/therapy during the study that could improve psoriasis are 
considered treatment failures. The baseline values will be assigned regardless of the observed data for 
continuous endpoints, zero will be assigned to im provement and percent improvement, and nonresponder 
status will be assigned to binary response variables. After applying the treatment failure rules, the 
remaining missing data will be assigned nonresponder status for binary variables. For the longitudinal 
analyses, treatment failure rules or missing data handling rules will not be applied.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
11
Approved , Date: [ADDRESS_1203921]. The 
followin g stepwise comparisons will be made to compare the efficacy of guselkumab to that of 
secukinumab at Week 48:
a.A non-inferiority margin of 10% was chosen based on a minimal clinically meaningful 
difference . This margin was also used as the non -inferiority margin for the ustekinum ab psoriasis 
study C0743T12 and the guselkumab psoriasis CNTO1959PSO3001 and CNTO1959PSO3002 
studies. To claim the non-inferiority of guselkumab tosecukinumab, the lower bound of the 
2-sided 95% confidence interval of P1 –P2 must be ≥ –10%, where P1 and P2 are the proportions 
of subjects achieving a PASI [ADDRESS_1203922] of guselkumab to secukinumab will 
be performed at 2- sided (α=0.05).
If both the non-inferiority test and the superiority test are positive, the major secondary hypotheses
comparing the guselkumab group and the secukinumab group will be tested sequentially . Otherwise, all 
remaining p -values will be considered nominal.
Major Secondary Analyses
For the major secondary analysis, all non-inferiority tests will be performed at 1-sided (α=0.025) with a 
non-inferiority margin of 10%. The major secondary analyses are:
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI 75response at both Week [ADDRESS_1203923] on this endpoint will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI 90 response at Week 12 will be performed.
 The non-i nferiority test comparing guselkumab with secukinu mab for the proportion of subjects 
achieving a PASI 75 response at Week 12 will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI [ADDRESS_1203924] on this endpoint will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving an IGA score of cl eared (0) at Week [ADDRESS_1203925] major secondary analysis will be 
performed only if the primary endpoint is positive for both non-inferiority and superiority, and the 
subsequent analysis will be performed only if the preceding analysis in the sequence is positive.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
12
Approved , Date: 5 October 2017Other Efficacy Analyses
In addition to the primary and major secondary analyses, the analyses for other efficacy endpoints will be 
performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI 90response at both Week 16and Week [ADDRESS_1203926] on this endpoint will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI 75response at Week 16 will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving a PASI 90 response at Week 16 will be performed.
 The non-inferiority test compari ng guselkumab with secukinumab for the proportion of subjects 
achieving a PASI [ADDRESS_1203927] on this endpoint will be performed.
 The non-i nferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving an IGA score of cleared (0) or minimal (1) at Week 1 6will be performed.
 The non-inferiority test comparing guselkumab with secukinumab for the proportion of subjects 
achieving an IGA score of cleared (0) or minimal (1) at Week 12 will be performed.
 The proportions of subjects who achieve a PASI 75 response at Week 48 among PASI 75 responders 
at Week 12 will be summarized by [CONTACT_1570].
 The proportions of subjects who achieve a PASI 90 response at Week 48 among PASI 90 responders 
at Week 16 will be summarized by [CONTACT_1570].
 The proportion sof subjects who achieve a PASI 50/75 /90/100 response over time through Week 48 
will be summarized by [CONTACT_1570].
 The proportion sof subjects who achieve anIGA score of cleared (0) response, IGA score of cleared 
(0) or minimal (1) response, and IGA of cleared (0), minimal (1), or mild (2)response over time 
through Week 48 will be summarized by [CONTACT_1570].
 The percentages of improvement from baseline in PASI over time through Week 48 will be 
summarized by [CONTACT_1570].
Safety such as AEs, vital signs, eC -SSRS,laboratory values and ECG parameters will be summarized 
statistics.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
13
Approved , Date: 5 October 2017TIME A ND EVENTS SCHE DULE
Phase ScreeningaActive Treatment Follow -up
Week 0 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48b56
Study Procedures
Screening/Administrative
Informed consent X
Medical history 
and demographicsX
Inclusion/
exclusion criteriaX X
Study Drug Administration
Randomization X
AdministrationcX X X X X X X X X X X X X X X
Safety Assessments
Physical 
examination 
(including skin 
exam)X X X
Vital signs X X X X X X X X X X X X X X X X X X
12-lead ECG X X X
Tuberculosis 
evaluationX X X X X X X X X X X X X X X X X X
Chest radiograph X
Urine pregnancy 
testd X X X X X X X X X X X X X X X X X X
Height X
Weight X
Concomitant therapy X X X X X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X X X
eC-SSRSeX X X X X X X X X X X X X X X
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
14
Approved , Date: 5 October 2017TIME A ND EVENTS SCHE DULE
Phase ScreeningaActive Treatment Follow -up
Week 0 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48b56
Study Procedures
Efficacy Assessments
IGA X X X X X X X X X X X X X X X X X X
PASI X X X X X X X X X X X X X X X X X X
Body  Surface Area 
(BSA )%X X
Clinical Laboratory Assessment
QuantiFERON -TB 
testf X
Hepatitis B and C 
serologyX
HIV antibody test X
Hem atology X X X X X X X X
ChemistrygX X X X X X X X
Lipid panelhX
Hs-CRP X
Pharm acokinetics and Immunogenicityi
Serum guselkumab 
concentrationX X X X X X X
Antibodies to 
guselkumabX X X X X X X
Biom arkers
Serum biomarkersjX X X X
Skin biopsy (RNA)kX X X
 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
15
Approved , Date: 5 October 2017TIME A ND EVENTS SCHE DULE
Phase ScreeningaActive Treatment Follow -up
Week 0 1 2 3 4 8 12 16 20 24 28 32 36 40 44 48b56
Study Procedures
Genetic (DNA) evaluations
Genetic (DNA) 
analysesm X
FOOTNOTES:
a: The screening visit should occur within approximately 4 weeks before the Week 0 visit.
b: All Week [ADDRESS_1203928] the Week 56 assessm ents.
c: All study procedures and evaluations should be completed before administration of study drug. Assessments for subjects who discontinue study agent administration or withdraw from 
the study arediscussed in Section 10.2.
d: Women of childbearing potential must have a negative urine pregnancy test before randomization, before study drug administ ration, and at all study visits.
e: The eC -SSRS should be completed by [CONTACT_863361], procedures, or other consultations to prevent influencing subject p erceptions,
f: A tuberculin skin test is additionally required if the QuantiFERON -TB Gold test is not app roved/registered in the country in which this study is being conducted.
g: Laboratory tests are listed in Section 9.6.
h: Subjects must fast (ie, n o food or beverages [except water]) for at least 8 hours before blood is drawn for lipid panel. All other visits can be nonfa sting.
i: All blood samples must be collected before study agent administration at visits when a study agent administration is sche duled. Details will be provided in the Laboratory Manual.
j Serum biomarker m easurements will include but are not limited to : serum IL -17A , IL-17F , and IL-22 . For subjects who discontinue from the study prior to Week 48, serum is not to be 
collected for me asurement of biomarkers.
k Biopsy samples for RNA and tissue histology will be collected only from subjects who consent to participate in the optional biopsy substudy. Biopsy samples will be used to assess the 
cellular and molecular profiles of psoriatic s kin lesions at baseline and during treatment.
 
m: Blood samples for genetic (DNA) analyses will be collected only from subjects who sign a separate consent form to participa te in the genetic (DNA) evaluations.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
16
Approved , Date: 5 October 2017ABBREVIA TIONS
BCG Bacille Calmette -Guérin
BSA body surface area
CSR clinical study report
DBL database lock
ECG electrocardiogram
eCRF electronic case report form
eC-SSRS electronic Columbia -Suicide Severity Rating Scale
eDC electronic data capture
GCP Good Clinical Practice
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IGA Investigator’s Global Assessment
IL interleukin 
IL-23R interleukin -[ADDRESS_1203929]
IWRS interactive web response system
mAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MTX methotrexate
NAb neutralizing antibodies
NCI-CTCAE National Cancer Institute -Comm on Term inology Criteria for Adverse Events
PASI Psoriasis Area and Severity Ind ex
PD pharmacodynamic(s)
PFS prefilled syringe 
PFS-U prefilled syringe assembled with the UltraSafe PLUS ™Passive Needle Guard
PK pharmacokinetic
PQC Product Quality Complaint
PsA psoriatic arthritis
SAP Statistical Analysis Plan
SC subcutaneous
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
Tc17 CD8+ T cells
Th17 T helper [ADDRESS_1203930] upper limit of normal
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
17
Approved , Date: 5 October [ZIP_CODE]. INTRODUCTION
Guselkumab (CNTO 1959) is a fully  human immunoglobulin G1 lambda monoclonal antibody 
(mAb) that binds to human interleukin (IL)-23 with high specificit y and affinity . The binding of 
guselkumab to IL-blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor
(IL-23R) , inhibiting IL -23-specific intracellular signaling and subsequent activation and cy tokine 
production. In this manner, guselkumab inhibits the biological activit y of IL-[ADDRESS_1203931] version of the Investigator's Brochure and Addenda for guselkumab.
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Background
The clinical development program to support use of guselkumab in the treatment of moderate to 
severe plaque -type psoriasis includes two Phase [ADDRESS_1203932] been completed, and formed 
the basis to proceed to Phase 3. Details about these 3individual studies are provided in the 
Investigator’s Brochure . Results from two of the Phase 3 studies (CNTO1959PSO3001 and 
CNTO1959PSO3002) are presented below. Specifically , these two Phase 3 studies were both 
conducted using placebo and an active comparator, adalimumab (HUMIRA®). In these studies, 
guselkumab demonstrated superior efficacy  to both placebo and adalimumab. The results of 
these 2 studies provide valuable benchmark data to assess the comparative efficacy  of 
guselkumab and secukinumab.
Phase 3 Study (CNTO1959PSO3 001, VOYAGE 1 )
Study  CNTO1959PSO3001 (VOYAGE 1 ) was a multicenter, Phase 3, randomized, double -blind, 
placebo- and active -comparator- controlled study  in subjects with moderate to severe plaque -type 
psoriasis with 3 parallel treatment groups: placebo, guselkumab 100 mg, and adalimumab. 
Subjects in the placebo group crossed over to guselkumab 100 mg beginning at Week 16. Inthat
study , 837 adult subjects were randomized to receive guselkumab (n=329) or adalimumab 
(n=334) or placebo (n=174).
At Week 16, a significantly  greater proportion of subjects randomized to guselkumab achieved 
the co-primar y endpoints of an Investigator’s Global Assessment (IGA)score of cleared (0) or 
minimal (1) and Psoriasis Area and Severit y Index (PASI ) 90 response (85.1% and 73.3%,
respectivel y;p<0.001 for both endpoints) compared with placebo (6.9% and 2.9% , respectivel y).
At Week 24, a significantly  higher proportion of subjects achieved IGA score of cleared (0), IGA 
score of cleared (0) or minimal (1), and PASI  90 response in the guselkumab group than in the 
adalimumab group. Similar to the observations at Week 24, a significantly higher proportion of 
subjects achieved an IGA score of cleared (0), an IGA score of cleared (0) or minimal (1), and a 
PASI  90 response in the guselkumab group than in the adalimumab group at Week 48.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
18
Approved , Date: [ADDRESS_1203933] infection. Through Week 16, the percentage of 
subjects with 1or more serious adverse events (SAEs) was 1.7% (n=3) in the placebo group, 
2.4% (n=8) in the guselkumab group and 1.8% (n=6) in the adalimumab group, and was 
comparable between the guselkumab (4.9% [n=16 ]) and adalimumab (4.5% [n=15 ]) groups 
through Week 48. The incidence of infections was comparable between placebo, guselkumab 
and adalimumab groups through Week 16, and between the guselkumab group (52.3%) andthe 
adalimumab group (50.2%) through Week 48. No opportunistic infections or active tuberculosis
(TB) were reported. No anaphy lactic orserum -sickness reactions were reported in the 
guselkumab group , and the incidence of injection site reactions was lower in the guselkumab 
group than the adalimumab group.
Phase 3 Study (CNTO1959PSO3 002, VOYAGE 2 )
Study  CNTO1959PSO3002 (VOYAGE 2) was a mul ticenter, Phase 3, randomized, double -blind, 
placebo- and active -comparator- controlled study  in subjects with moderate to severe plaque -type 
psoriasis with 3 treatment groups: placebo, guselkumab 100 mg, and adalimumab. Inthat study , 
992 adult subjects were randomized to either the placebo (n=248), guselkumab (n=496) ,or 
adalimumab (n=248) treatment groups at Week 0. Subjects in the placebo group crossed over to 
guselkumab 100 mg beginning at Week 16. This study  evaluated the benefit of maintenance 
therap y using a randomized withdrawal design starting at Week 28.
At Week 16, a significantly  greater proportion of subjects randomized to guselkumab achieved 
the co-primary  endpoints of an IGA score of cleared (0) or minimal (1) and a PASI 90 response 
(84.1% and70.0%, respectively ;p<0.001 for both endpoints) compared with placebo (8.5% and 
2.4%, respectivel y).In addition , a significantly greater proportion of subjects achieved IGA 
score of cleared (0), IGA score of cleared (0) or minimal (1), and PASI  [ADDRESS_1203934] common AEs.The percentage of subjects with 1
or more SAEs was comparable between the placebo and guselkumab groups, and slightly  higher 
in the adalimumab group. The incidence of infections was comparable between placebo, 
guselkumab, and adalimumab groups through Week 16. Through Week 28, the proportion of 
subjects experiencing 1 or more AEs was comparabl e between the guselkumab and adalimumab
groups. Two adalimumab -treated subjects reported active TB. No opportunistic infections were 
reported. No anaph ylactic or serum -sickness reactions were reported.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
19
Approved , Date: 5 October [ZIP_CODE].2. Comparator
Cosentyx®(secukinumab )
Secukinumab (Cosent yx, Novar tis Pharmaceuticals Corporation), a recombinant, high affinity , 
fully  human mAb that selectivel y targets IL17A, is the first approved anti-IL-17 mAb for the 
treatment of moderate to severe plaque psoriasis. Secukinumab was selected as the active 
comparator because it is one of the newer, subcutaneously  (SC) self-administered agents shown 
to achieve very high levels of efficacy  in moderate to severe plaque psoriasis, and therefore 
provides a valuable and relevant benchmark for comparison with guselkumab. Subjects 
randomized to secukinumab must be dosed according to the labeled dose regimen for plaque 
psoriasis: 300mg at Week s 0, 1, 2, 3, and 4 followed by 300mg q4w (through Week 44 in this 
study ).
For further information regarding secukinumab ,refer to the current prescribing information.
1.3. Overall Rationale for the Study
1.3.1. Role of IL -23 in the Treatment of Psoriasis
Psoriasis pathogenesis involves the dysregulation of IL-23- and IL-17-mediated immune 
responses. IL-23 is a key regulatory  cytokine produced by [CONTACT_863362], expansion andmaintenance of CD4+IL-17 producing T helper 17 
(Th17) cells, IL-22producing T helper 22cells, and CD8+ T cells (Tc17) .9Th17 cells secrete 
several inflammatory  mediators including IL-17A, IL-17F, and IL-22. In addition to being 
produced by [CONTACT_78443]17 cells, IL-17A is also produced by γδ-T cells and Tc17 cells, which are also 
regulated to some extent by [CONTACT_8668]-[ADDRESS_1203935] the differentiation, expansion, and maintenance of 
Th17 and Tc17 cells providing sustained disruption of Th17 and Tc17 cell involvement in 
psoriasis lesions. Antagonism of soluble IL-17 inhibits local IL-17-mediated pathology  in 
psoriasis lesions in addition to soluble IL-17 produced by [CONTACT_105]-Th17 cells. Selective inhibition of 
IL-23R- expressing Th17 and Tc17 cells, the source of IL-17 in psoriasis lesions, by [CONTACT_863363]-23, may  yield sustained clinical benefit in psoriasis.
Guselkumab, a human mAb specificall y targets IL-23. A rapi[INVESTIGATOR_863335]-23/IL -[ADDRESS_1203936]  contributes to the chroni c inflammation underly ing the 
pathophy siology  of many  immune -mediated diseases,14,19including psoriasis.8In addition, 
susceptibility  to psoriasis, psoriatic arthritis ( PsA), and inflam matory  bowel disease has been 
shown to be associated with genetic polymorphisms in IL-23/IL -23R components.2,4,7,11,13
Finally , the clinical response to guselkumab observed in Phase 1, 2, and 3 psoriasis studies 
demonstrates the specific importance of IL-23 in the pathogenesis of plaque -typepsoriasis and 
supports further investigation of the clinical benefit of guselkumab compared to secukinumab.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
20
Approved , Date: 5 October [ZIP_CODE].3.2. Dose Rationale
A dose regimen of guselkumab 100 mg at Weeks 0 and 4 and q8w thereafter was selected for the 
global Phase 3 studies of guselkumab for the treatment of moderate to severe plaque -type
psoriasis. This dose regimen was chosen based on results of the guselkumab dose-ranging study  
(CNTO1959PSO2001) in subjects with moderate to severe plaque -type psoriasis and 
pharmacokinetic (PK) /pharmacody namic (PD) modeling based on the data from that study .The
same dose regimen studied in the global phase 3 program will be used in this study .
1.3.3. Rationale for Trial Design and Efficacy  Analyses
The proposed randomized, blinded, two -active -arm trial will evaluate the relative performance of 
guselkumab and secukinumab utilizing a comprehensive battery  of endpoints (eg, PASI  75, 90, 
and 100) at various timepoints (eg, Week 12 and Week 48) using rigorous statistical 
methodology  to control for multiplicity .
The statistical analyses will employ  a sequential testing approach to control for multiplicity  that 
includes both superiority  and non -inferiority  testing for specified endpoints.
While the ultimate goal of the trial is to demonstrate that the efficacy  of guselkumab is superior 
to secukinumab for PASI 90 at Week 48, initial testing for non-inferiority  isincluded for this 
endpoint because the overall profile of guselkumab will likely be favorable compared with 
secukinumab (in terms of potential for increased compliance and lesser patient burden) ,even if 
relative efficacy  is no worse for this endpoint.
2. OBJECTIVES , ENDPOINTS, AND HYPOTHESES
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary O bjective
The primary  objective is to evaluate the efficacy  of guselkumab compared with secukinumab for 
the treatment of subjects with moderate to severe plaque- type psoriasis .
Secondary Objective s
The secondary  objective sare to assess :
The safety  and tolerability  of guselkumab in subjects with moderate to severe plaque -type 
psoriasis.
The PK and immunogenicity  of guselkumab after subcutaneous (SC) administrations in 
subjects with moderate to severe plaque -type psoriasis.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
21
Approved , Date: [ADDRESS_1203937] oratory objectives are to explore :
The PD effects (biomarkers) of treatment with guselkumab or secukinumab in subjects with 
moderate to severe plaque -type psoriasis.
The impact of treatment with guselkumab or secukinumab on psoriasis skin lesion gene 
expression profiles and cellular content in subjects with moderate to severe plaque -type 
psoriasis.
  
The association between genetic factors and 1) the efficacy  of guselkumab or secukinumab 
and 2) psoriasis.
2.1.2. Endpoints
Primary Endpoint
The primary  endpoint in this study  is the proportion of subjects who achieve a PASI 90 response 
at Week 48, comparing the guselkumab group and the secukinumab group.
Major Secondary Endpoints
The major secondary  endpoints to compare the guselkumab group and the secukinumab group
are listed below and are the proportion of subjects who achieve:
A PASI  75 response at both Week 12 and Week 48.
APASI  90response at Week 12.
APASI  75response at Week 12.
A PASI  100 response at Week 48 .
An IGA score of cleared (0) at Week 48.
Other Secondary Endpoints
The other secondary  endpoints to compare the guselkumab group and the secukinumab 
group are listed below and are the proportion of subjects who achieve:
A PASI  90 response at both Week 16 and Week 48.
A PASI  75 response at Week 16 .
A PASI  90 response at Week 16 .
A PASI  90 response at all 7 visits from Week 24 through Week 48.
An IGA score of cleared (0) or minimal (1) at Week 16.
An IGA score of cleared (0) or minimal (1) at Week 12.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
22
Approved , Date: 5 October 2017The proportions of subjects who achieve a PASI 75 response at Week 48 among PASI 75 
responders at Week 12 .
The proportions of subjects who achie ve a PASI 90 response at Week 48 among PASI 90 
responders at Week 16 .
The proportions of subjects who achieve a PASI  50/75 /90/100 response over time through 
Week 48.
The proportions of subjects who achieve an IGA score of cleared (0) response, IGA score of
cleared (0) or minimal (1) response, and IGA of cleared (0), minimal (1), or mild (2)
response over time through Week 48 .
Percent ages of improvement in PASI  over time through Week 48 .
2.2. Hypotheses
The proposed randomized, blinded, two -active -arm trial will evaluate the relative performance of 
guselkumab and secukinumab utilizing a comprehensive battery  of endpoints (eg, PASI  75, 90, 
and 100) at various timepoints (eg, Week 12 and Week 48) using rigorous statistical 
methodology  to control for multiplicity .
While the ultimate goal of the trial is to demonstrate that the efficacy  of guselkumab is superior 
to secukinumab for PASI 90 at Week 48,initial testing for non-inferiority  isincluded for this 
endpoint because the overall profile of guselkumab will likely  be favorable compared with 
secukinumab (in terms of potential for increased compliance and lesser patient burden) , even if 
final results only  indicate the relative efficacy  is no worse for this endpoint.
The primary  hypothes es arethat guselkumab treatment is non-inferior to secukinumab as 
assessed by [CONTACT_216574] a PASI 90response at Week 48with a non-
inferiority  margin of 10% and, once non -inferiority  is established, that guselkumab is superior to 
secukinumab as assessed by [CONTACT_216574] a PASI  90 response at 
Week 48.
The major secondary  hypotheses are that g uselkumab treatment is:
Non-inferior to secukinumab for the maintenance of a PASI 75 response as assessed by [CONTACT_863354] a PASI 75 response at both Week 12 and Week 48 with 
a non-inferiorit y margin of 10% and, once non-inferiorit y is established, that guselkumab is 
superior to secukinumab as assessed by [CONTACT_863355] a PASI 75 
response at both Week 12 an d Week 48 .
Non-inferior to secukinumab at Week 12 as assessed by [CONTACT_863364] 90 at Week 12 with a non -inferiority  margin of 10% .
Non-inferior to secukinumab at Week 12 as assessed by [CONTACT_863364] 75 at Week 12 with a non- inferiority  margin of 10% .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
23
Approved , Date: 5 October 2017Non-inferior to secukinumab at Week 48 as assessed by [CONTACT_863364] 100 at Week 48 with a non-inferiorit y margin of 10% and, once non-
inferiority  is established, that guselkumab is superior to secukinumab as assessed by [CONTACT_863354] a PASI 100 response at Week 48 .
Non-inferior to secukinumab at Week 48 as assessed by [CONTACT_863365] (0) at Week 48 with a non-inferiority  margin of 10% and, 
once non-inferiorit y if established, that guselkumab is superior to secukinumab as assessed 
by [CONTACT_863366] (0) at Week 48 .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of S tudy  Design
This is a Phase 3, random ized, double -blind, multicenter, active -comparator -controlled study  in 
subjects with moderate to severe plaque -type psoriasis. The target population is adult men or 
women, with a diagnosis of plaque -type psoriasis (with or without PsA) for at least 6months 
before the first administration of study  drug. Subjects must have moderate to severe plaque -type 
psoriasis defined by [CONTACT_78442] ≥3, PASI  ≥12, and involved body  surface area (BSA) ≥10%. Subjects 
must be candidates for either systemic therapy  or phototherap y for psoriasis, and may have 
previously  received some systemic therapi[INVESTIGATOR_863336] y for psoriasis. Subjects with 
nonplaque forms of psoriasis (eg, erythrodermic, guttate, or pustular) or with drug-induced 
psoriasis (eg , a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium 
channel blockers, or lithium) are excluded. Subjects who have ever received guselkumab or 
secukinumab are also excluded.
Key features of study  drug administration for each treatment group are outlined below; for 
details regarding concomitant placebo administrations to maintain the blind, see Section 6.
Week 0 through Week 44 (Blinded Treatment Period)
As depi[INVESTIGATOR_356289] 1, approximately  1,040 subjects who satisfy  all inclusion and exclusion 
criteria will be randomized in a 1: 1 ratio to 1 of 2 treatment arms:
Group I(n=520 ): guselkumab 100mg SC at Weeks 0, 4, 12, and q8w thereafter through 
Week 44.
Group II(n=520): secukinumab 300mg SC at Weeks 0, 1, 2, 3, 4 and q4w thereafter 
through Week 44.
After Week 44 through Week 56 (Follow- up Period)
The follow -up period will begin after Week 44 and extend through Week 56.
There is 1 database lock (DBL) in this study at Week 56. The sponsor, the investigators ,subjects, 
and site monitors will be unblinded after the Week [ADDRESS_1203938] completes the Week 56 visit.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
24
Approved , Date: 5 October 2017A pharmacogenomic blood sample will be collected from subjects who consent separately  to this 
component of the study  (where local regulations permit ). Subject participation in 
pharmacogenomic research is optional.
A diagram of the stud y design is provided in Figure 1.
Figure 1: Schematic Overview of the Study
3.2. Study Design Rationale
This Phase 3, randomized, double -blind, multicenter study  will evaluate the comparative efficacy 
and assess the safet y of guselkumab, compared with secukinumab for the treatment of subjects 
with moderate to severe plaque -type psoriasis.
Multiple therapeutic options exist for the treatment of moderate to severe psoriasis; however, 
none of the currently  approved agents, including several highl y effective biologic agents, can 
provide complete clearance of disease in all patients. Several studies suggest that complete 
clearance is associated with quantifiable improvement sin quality  of life,21,18,16and is 
increasingl y sought by [CONTACT_863367] y effective therapi[INVESTIGATOR_863337]. A recent publication reported that patients who were considered to be responders, but 
lacked complete clearance, may  still experience negative impact on their health -related quality  of 
life as compared to those patien ts who achieved complete clearance. The patients who were 
considered cleared had a substantial improvement in their quality  of life.17While availab le 
clinical studies have demonstrated that secukinumab treatment leads to rapid, clinically 
significant improvement in subject s with psoriasis ,20,6it is anticipated that guselkumab treatment 
will result in higher proportions of patients achieving a nearl y clear (PASI  90) or clear 
(PASI 100) response compared with treatment with secukinumab over 1 year of treatment .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
25
Approved , Date: [ADDRESS_1203939], the primary  endpoint is 
at W eek 48 and it is not feasible to keep patients with moderate to severe psorias is on placebo for 
that period of time. Second, given the historically  low placebo rates observed in large Phase 3 
moderate to severe psoriasis studies, and the proven efficacy  of these two highl y effective drugs, 
the value of the placebo arm for the purpose of demonstratin g assay  sensitivity  is minimal. The 
efficacy  of secukinumab was established (in individual studies vs placebo) using primary 
endpoints at Week 12.6However, it is known that neither agent reaches their maximal effect 
until after Week 12. In addition, psoriasis is a chronic disease that often requires chronic 
treatment, such that longer -term outcomes are clinically  important. Therefore, endpoints at 
Weeks 12, 16 , and 48 (with the primary  endpoint of PASI 90at Week 48) were selected to 
provide the most clinically meaningful evaluations of the relative performance of the 
2treatments. Ultim ately , this study  is designed to show superiority  of efficacy of guselkumab
after [ADDRESS_1203940] s of guselkumab and secukinumab , to further 
defin e the mechanism of action of blocking IL -23 compared to blocking IL-17A in psoriasis, and 
to aid in evaluating the drug’s clinical response relationship. Serum biomarkers will be collected 
in all subjects to assess PD markers associated with the response to guselkumab and 
secukinumab.
Additionally , 3optional substudies are planned: skin biopsy ,  and genetic 
analysis. Skin biopsies will be collected in a subset of subjects at selected sites who consent to 
participate in theoptional skin biops y substudy  to determine gene expression profiles and 
cellular content associated with response to guselkumab or secukinumab. Epi[INVESTIGATOR_863338] .These exploratory  analyses 
of psoria tic skin lesions may help to further define the cellular and molecular mechanism of 
action associated with blockade of IL-23 compared to blockade of IL-17A in psoriasis.  
 
 
 
 
 
It is recognized that genetic variation can be an important contributory  factor to inter-individual 
differences in drug distribution and response and can also serve as a marker for disease 
susceptibility  and prognosis. Genetic (DNA) analy sis may help to explain inter-individual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to a drug. The goal of the genetic (DNA) analysis is to collect a single DNA sample 
(from whole blood) to allow the identification of genetic factors , including single nucleotide 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
26
Approved , Date: [ADDRESS_1203941] satisfy  all of the following criteria to be enroll ed in the study :
Subject population -related inclusion criteria
1. Be a man or a woman at least 18 years of age (or the legal age of consent in the 
jurisdiction in which the study  is taking place).
2. Have a diagnosis of plaque -type psoriasis (with or without PsA) for at least 6months 
before the first administration of study  drug.
3. Have a PASI ≥[ADDRESS_1203942] an IGA ≥[ADDRESS_1203943] an involved BSA ≥10% at screening and at baseline.
6. Be a candidate for phototherapy  or systemic treatment for psoriasis (either naïve or 
history  of previous treatment).
7. Be considered, in the opi[INVESTIGATOR_871], suitable candidates for secukinumab
(Cosenty x) therap y according to their country 's appro ved secukinumab product labeling.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
27
Approved , Date: [ADDRESS_1203944] be either:
Not of childbearing potential: premenarchal; postmenopausal (>[ADDRESS_1203945] 
6months and a serum follicle -stimulating hormone level >40IU/L); permanently 
sterilized (eg, tubal occlusion, hysterectom y, bilateral salpi[INVESTIGATOR_1656] ); or otherwise 
be incapable of pregnancy.
Of childbearing potential and practicing a highl y effective method of birth control, 
consistent with local regulations regarding the use of birth control methods for 
subjects participating in clinical studies : eg, established use of oral, injected or 
implanted hormonal methods of contraception; placement of an intrauterine device 
or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or 
cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository  (if available 
in their locale) ; male partner sterilization (the vasectomized partner should be the 
sole partner for that subject); true abstinence (when this is in line with the preferred 
and usual lifesty le of the subject).
Note: If a female subject’s childbearing potential changes after start of the study  (eg, a 
woman who is not heterosexually  active becomes active, a premenarchal woman 
experiences menarche), she must begin practicing a highl y effective method of birth 
control, as described above.
9. A woman of childbearing potential must have a negative urine pregnancy  test at 
screening and at Week [ADDRESS_1203946] agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study  and for at least [ADDRESS_1203947] agree to use a barrier method of birth control (eg, either a 
condom [with spermicidal foam/gel/film/cream/suppository  if available in their locale] 
or a partner with an occlusive cap [diaphragm or cervical/vault caps] plus spermicidal 
foam/gel/film/cream/suppository  if available in their locale ), during the study  and for at 
least [ADDRESS_1203948] 
administration of guselkumab.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
28
Approved , Date: 5 October 2017Infectious disease -related inclusion criteria
12. Are considered eligible according to the following TB screening criteria:
Have no history  of latent or active TB before screening.
oAn exception is made for subjects who have a history  of latent TB and
are currentl y receiving treatment for latent TB,
will initiate treatment for latent TB before the first administration of 
study  drug,
or have documentation of having completed appropriate treatment for 
latent TB within [ADDRESS_1203949] administration of study  drug.
oIt is the responsibility of the investigator to verify the adequacy  of previous 
anti-TBtreatment and provide appropriate documentation.
Have no signs or sy mptoms suggestive of active TB upon medical history and/or 
physical examination.
Have had no recent close contact [CONTACT_4490] a person with active TB or, if there has 
been such contact, will be referred to a physician specializing in TB to undergo 
additional evaluation and, if warranted, receive appropriate treatment for latent 
TB before the first administration of study  drug.
Within [ADDRESS_1203950] a negative 
QuantiFERON®-TB Gold test result, or have a newl y identified positive 
QuantiFERON -TB Gold test result (Attachment 3) in which active TB has been 
ruled out and for which appropriate treatment for latent TB has been initiated 
before the first administration of study  drug. Within 2months before the first 
administration of study drug, anegative tuberculin skin test, or a newly 
identified positive tuberculin skin test in which active TB has been ruled out and 
for which appropriate treatment for latent TB has been initiated before the first 
administration of study  drug, is additional ly required if the QuantiFERON -TB 
Gold test is not approved/registered in that country  or the tuberculin skin test is 
mandated b y local health authorities.
NOTE: The QuantiFERON -TB Gold test and the tuberculin skin test are not 
required at screening for subjects with a history  of latent TB and ongoing 
treatment for latent TB or documentation of having completed adequate 
treatment as described above; subjects with documentation of having completed 
adequate treatment as described above are not required to ini tiate additional 
treatment for latent TB.
Have a chest radiograph (posterior -anterior and lateral views, or per country  
regulations where applicable), taken within [ADDRESS_1203951] administration of study drug. For information on Bacille 
Calmette -Guérin (BCG) vaccination, see Inclusion Criterion 14.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
29
Approved , Date: [ADDRESS_1203952] of laboratory  values is 
permitted:
Hemoglobin ≥10 g/dL (SI: ≥100 g/L)
White blood cells ≥3.5 x 103/µL (SI: ≥3.5 GI/L)
Neutrophil s ≥1.5 x 103/µL (SI: ≥1.5 GI/L)
Platelets ≥100 x 103/µL (SI: ≥100 GI/L)
Serum creatinine ≤1.5 mg/dL (SI: ≤137μmol/L )
Aspartate aminotransferase ≤2 × upper limit of normal (ULN)
Alanine aminotransferase ≤2 × ULN
Alkaline phosphatase ≤2 × ULN
Other inclusion criteria
16. Agree to avoid prolonged sun exposure and avoid use of tanning booths or other 
ultraviolet light sources during stud y.
17. Be willing and able to adhere to the prohibitions and restrictions specified in this 
protocol.
18. Must sign an informed consent form (ICF) [(or their legally  acceptable representative 
must sign)] indicating that he or she understands the purpose of, and procedures 
required for, the stud y and is willing to participate in the study. 
19. Must sign a separate ICFif he or she agrees to provide an optional DNA sample for 
research (where local regulations permit). Refusal to give consent for the optional DNA 
research sample does not exclude a subject from participation in the study .
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study :
Medical history- related exclusion criteria
1. Has a history  or current signs or sy mptoms of severe, progressive, or uncontrolled renal, 
cardiac, vascular, pulmonary , gastrointestinal, endocrine, neurologic, hematologic, 
rheumatologic, ps ychiatric, or metabolic disturbances.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
30
Approved , Date: 5 October [ZIP_CODE]. Has unstable cardiovascular disease, defined as a recent clinical deterioration (eg, 
unstable angina, rapid atrial fibrill ation) in the last [ADDRESS_1203953] 3 months.
3. Has unstable suicidal ideation or suicidal behavior, that may be de fined as an electronic 
Columbia -Suicide Severity  Rating Scale (eC-SSRS )rating at screening of: Suicid al 
ideation with intention to act (“4”), Suicidal ideation with specific plan and intent (“5”), 
or a suicide attempt (interrupted suicide attempt, aborted suicide attempt, or preparatory  
behaviors for making a suicide attempt) in the last [ADDRESS_1203954] will be made at the judgment of the investigator.
4. Has a transplanted organ (with exception of a corneal transpl ant >3months before the 
first administration of study  drug).
5. Has a history  of an infected joint prosthesis, or has received antibiotics for a suspected 
infection of a joint prosthesis, if that prosthesis has not been removed or replaced.
6. Is pregnant, nursing, or planning a pregnancy  (both men and women) while enrolled in 
this study  and within [ADDRESS_1203955] administration of study  drug.
7. Has a nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular).
8. Has curre nt drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of 
psoriasis from beta blockers, calcium channel blockers, or lithium).
9. Has had major surgery  (eg, requiring general anesthesia and hospi[INVESTIGATOR_059]) within 
8weeks before screening, or will not have fully  recovered from such surgery , or has 
such surgery  planned during the time the subject is expected to participate in the study  
(56weeks).
Note: Subjects with planned surgical procedures to be conducted under local anesthesia 
may participate.
10. Is known to have had a substance abuse (drug or alcohol) problem within the previous 
12months.
11. Had a known allergy  or sensitivity  to products containing latex.
Concomitant or previous medical therapi[INVESTIGATOR_014]- related exclusion criteria
12. Has previousl y received guselkumab or secukinumab.
13. Has an y contraindications to the use of secukinumab per local prescribing information.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
31
Approved , Date: [ADDRESS_1203956] administration of study  drug (including but not limited to 
ustekinumab, tildrakizumab [MK3222], risankizumab [BI-655066], ixekizumab 
[LY2439821], or brodalumab [AMG 827]) with the exception of secukinumab (which is 
completely excluded).
17. Has received natalizu mab, belimumab, or agents that modulate B cells or T cells (eg, 
rituximab, alemtuzumab, abatacept, or visilizumab) within 12months of the first 
administration of study  drug.
18. Has received any systemic immunosuppressants (eg, methotrexate [MTX], azathi oprine, 
cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus) or 
anakinra within [ADDRESS_1203957] administration of study  drug.
19. Has received phototherapy  or any systemic medications/treatments that could affect 
psoriasis or IGA evaluations (including, but not limited to, oral or injectable 
corticosteroids, retinoids, 1,25-dihydroxy vitamin D3 and analogues, psoralens, 
sulfasalazine, hydroxy urea, apremilast, fumaric acid derivatives, herbal treatments, or 
traditional Taiwanese, Korean, or Chinese medicines) within [ADDRESS_1203958] 
administration of study  drug.
20. Has used topi[INVESTIGATOR_5910]/treatments that could affect psoriasis or IGA evaluations 
(including, but not limited to, corticosteroids, anthralin, calcipotriene, topi[INVESTIGATOR_26445] D 
derivatives, retinoids, tazarotene, methoxsalen, trimethy lpsoralens, pi[INVESTIGATOR_031], 
tacrolimus, or topi[INVESTIGATOR_863339], Korean, or Chinese medicines) within 
2weeks of the first administration of study  drug.
21. I s currently  receiving lithium, antimalarials, or intramuscular (IM) gold, or have 
received lithium, antimalarials, or IM gold within [ADDRESS_1203959] administration of 
study  drug.
22. Has received an experimental antibody  or biologic therapy  within the previous 
6months, or received any other experimental therapy  or new investigational agent 
within 30 days or 5 half-lives (whichever is longer) of any study  drug administration or 
is currentl y enrolled in another study using an investigational agent or p rocedure.
23. Has received, or is expected to receive, any live virus or bacterial vaccination within [ADDRESS_1203960] administration of study  drug. For BCG vaccine, see Exclusion 
Criterion 24 .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
32
Approved , Date: [ADDRESS_1203961] has known allergies, hypersensitivity , or intolerance to guselkumab or its 
excipi[INVESTIGATOR_840] (refer to Investigator's Brochure) or secukinumab or its excipi[INVESTIGATOR_840].
Infections or predisposition to infections
27. Has a history  of chronic or recurrent infectious disease, including but not limited to 
chronic renal infection, chronic chest infection (eg, bronchiectasis), recurrent urinary  
tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal 
infection (mucocutaneous candidiasis), or open, draining, or infecte d skin wounds or 
ulcers.
28. Has a history  of active granulomatous infection, including histoplasmosis or 
coccidioidomy cosis, before screening. Refer to Inclusion Criterion [ADDRESS_1203962] administration of study  drug that 
shows an abnormalit y suggestive of a malignancy or current active infection, including 
TB.
30. Has had a nontuberculous mycobacterial infection or opportunistic infection (eg, 
cytomegalovirus, pneumocy stosis, aspergillosis). Subjects with a history  of esophageal 
candidiasis or thrush would also be exceptions to this criterion.
31. Has persistently  indeterminate (indeterminate on repeat sampling) QuantiFERON -TB 
Gold test results. I ndeterminate results should be handled as described in Section 9.1.2 .
32. Is infected with human immunodeficiency  virus (HIV, positive serology  for HIV 
antibody ).
33. Tests positive for hepatitis B virus (HBV) infection (Attachment 5) or who are 
seropositive for antibodies to hepatitis C virus (HCV), unless they  have [ADDRESS_1203963] result at screening
34. Has or has had a serious infection (eg, sepsis, pneumonia or py elonephritis), or has been 
hospi[INVESTIGATOR_863340] 2 months 
before screening.
35. Has or has had herpes zoster within the 2 months before screening.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
33
Approved , Date: 5 October 2017Malignancy or increased potential for malignancy
36. Currently  has a known malignancy  or has a history  of malignancy  within 5 years before 
screening (with the exception of a nonmelanoma skin cancer that has been adequatel y 
treated with no evidence of recurrence for at least [ADDRESS_1203964] study  drug administration).
37. Has a history  of lymphoproliferative disease, including lymphoma; a history  of 
monoclonal gammopathy of undetermined significance; or signs and symptoms 
suggestive of possible lymphoproliferative disease, such as lymphadenopathy  or 
splenomegaly .
Other exclusion criteria
38. Is unable or unwilling to undergo multiple venipunctures because of poor tolerability  or 
lack of eas y access to veins.
39. Lives in an institution on court or authorit y order.
40. Has any condition that, in the opi[INVESTIGATOR_871], would make participation not 
be in the best interest (eg, compromise the well- being) of the subject or that could 
prevent, lim it, or confound the protocol- specified assessments.
41. Is an employ ee of the investigator or study  site, with direct involvement in the proposed 
study  or other studies under the direction of that investigator or study  site, as well as 
family  members of the employ ees or the investigator.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If thesubject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given such 
that he or shenolonger meet sall eligibility  criteri a, then the subject should be excluded from 
participation in the study . Section 9.1.3 , Screen Failure/Rescreening , describes options for 
retesting. Section 17.4, Source Documentation, describes the required documentation to support 
meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. A woman of childbearing potential who is heterosexually active must remain on a 
highl y effective method of birth control (Inclusion Criterion 8) during the study  and for 
at lea st [ADDRESS_1203965] administration of guselkumab.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
34
Approved , Date: [ADDRESS_1203966] agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study  and forat least [ADDRESS_1203967] agree to use a barrier method of birth control (ie, male condom, female 
diaphragm or cervical cap, or condom, Inclusion Criterion 11) during the study  and for 
at least [ADDRESS_1203968] comply  with restrictions on concomitant medications and therapi[INVESTIGATOR_393365] y (Section 8).
8. Subjects must avoid prolonged sun exposure and avoid use of tanning booths or other 
ultraviolet light sources during the stud y.
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2treatment groups based on a computer -generated randomization schedule prepared before 
the study  by [CONTACT_43754]. The randomizat ion will be balanced by 
[CONTACT_111126] y permuted blocks and will be stratified by [CONTACT_3885]. The interactive web 
response system (IWRS) will assign a unique treatment code, which will dictate the treatment 
assignment and matching study  drug kit for the subject. The requestor must use his or her own 
user identification and personal identification number when contact[CONTACT_23790], and will then 
give the relevant subject details to uniquely  identify  the subject.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
35
Approved , Date: 5 October 2017Data that may potentially  unblind the treatment assignment ( eg,treatment allocation, study  drug
preparation/accountability  data[including unblinded personnel] ,and administration of study  
drug (see details in Section 6) will be ha ndled with special care to ensure that the integrity  of the 
blind is maintained and the potential for bias is minimized. This can include making special 
provisions, such as segregating the data in question from view by  [CONTACT_473], clinical team, 
or others as appropriate until the time of DBL and unblinding.
Under normal circumstances, the blind should not be broken for subjects, investigators, or site 
monitors until the Week 56 database is locked and finalized. Otherwise, the blind should be 
broken only if specific emergency  treatment/course of action would be dictated by [CONTACT_184903]. In such cases, the investigator may  in an emergency determine the 
identity  of the treatment by  [CONTACT_23793]. It is recommended that the investigator contact 
[CONTACT_97499], before breaking the 
blind. Telephone contact [CONTACT_97500] 24hours per day, 
7days per week. In the event the blind is broken, the sponsor must be informed as soon as 
possible. The date and reason for the unblinding must be documented by [CONTACT_8784], in the 
appropriate section of the electronic case report form (eCRF), and in the source document. The
documentation received from the IWRS indicating the code break must be retained with the 
subject's source documents in a secure manner.
Subjects who have had their treatment assignment unblinded should continue to return for 
scheduled evaluations. The dec ision to continue or discontinue study  treatment for these subjects 
will be based upon consultation of the investigator with the medical monitor.
6. DOSA GE A ND A DMINISTR ATION
A 100mg/mL  solution of guselkumab in a single -use prefilled syringe (PFS) assembled with the 
UltraSafe PLUS™Passive Needle Guard (PFS -U) device will be used. Subjects who are 
randomized to the guselkumab treatment arm will receive 2 injections: 1injection of active 
guselkumab and 1injection of placebo when guselkumab is scheduled to be administered
(Weeks 0, 4, 12, 20, 28, 36, 44) or 2 injections of placebo when no guselkumab is scheduled to 
be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40) .The purpose of administering 2injections 
is to mimic the 2injections required for each secukinumab dose, and to thus maintain the blind . 
Commercially  available secukinumab (Cosent yx) will be supplied as a single -use PFS and 
administered according to the manufacturer’s directions. Each 300mg dose is given as 2SC 
injections of 150mgeach. An appropriatel y qualified, unblinded member of the study  staffwill 
administer the drug and will have no other role in the conduct of the study .
All study  drug injections will be administered at the investigational site. With the exception of 
the unblinded site personnel who dispense and/or administer the investigational product, all other 
site personnel and subjects will remain blinded to the treatment assignments until the last subject 
completes Week [ADDRESS_1203969] the ability  to physically  blind and/or separate the blinded subject from the unblinded 
administrator. A physical barrier must be used such that the study  drug can be administered by 
[CONTACT_863359], and the subject an d other site personnel remain blinded.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
36
Approved , Date: [ADDRESS_1203970] s will attend visits within a range of ± 3days. 
After Week 4and through Week 44,it is expected that all visits will occur within a range of 
± 7days. Any visits outside of these ranges should be discussed with the sponsor. If a study  visit 
occu rs outside the specified visit window, the subject should then resume his or her normal dose 
schedule relative to the baseline visit (Week 0)as soon as possible . All other follow -up study  
visits should occur within ± [ADDRESS_1203971]’s source notes .
Study -site personnel will maintain a log of all study  drug administered. Drug supplies for each 
subject will be inventoried and accounted for.Information regarding study  drug administrations
that are administered outside of the scheduled windows or missed will be recorded. Subject 
charts and worksheets may be reviewed and compared with the data entries on the eCRFs to 
ensure accuracy . Although it is understood that treatment may be interrupted for many reasons, 
compliance with the treatment schedule is strongly encouraged.
8. CONCOMITA NT THERA PY
Concomitant therapi[INVESTIGATOR_863341] [ADDRESS_1203972] dose of study  drugfor randomized subjects . Concomitant therapi[INVESTIGATOR_863342] 56only in conjunction with SAEs that meet the criteria 
outlined in Section 12.3.2 . Serious Adverse Events.
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements) different from the study  drug, as well as all shampoos used to treat psoriasis, 
moisturizers, or emol lients, must be recorded in the eCRF.Modification of an effective 
preexisting therap y should not be made for the explicit purpose of entering a subject into the 
study .
If a prohibited therap y is administered during the blinded active treatment phase (ie, Week 0 to 
Week 44 - unless agreed to by [CONTACT_7195] ), the subject should be discontinued from 
study  treatment. If a prohibited therap y is initiated during the safety follow -up period (Week 48 
to Week 56), the subject should still complete his or her final study  visit at Week 56, and the 
medication should be recorded as a concomitant medication.
The sponsor must be notified in advance (or as soon as possible therea fter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
8.1.1. Concomitant Medications for Treatment of Psoriasis
[IP_ADDRESS]. Topi[INVESTIGATOR_863343] (eg, corticosteroids, tar, 
anthralin, calcipotrien e, tazarotene, methoxsalen, pi[INVESTIGATOR_031], tacrolimus, and traditional 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
37
Approved , Date: 5 October 2017Taiwanese, Korean, or Chinese medicines) are not permitted at any time during the study . The 
only allowable concomitant treatments for psoriasis throughout the study  are shampoos 
(contai ning tar or salicylic acid only) and topi[INVESTIGATOR_213118]. Subjects should not use these 
topi[INVESTIGATOR_12450] (shampoos, moisturizers) on the day of a study  visit. Nonmedicated shampoos 
may be used on the day  of the study  visit.
[IP_ADDRESS]. Phototherapy  or Systemic Therapy  for Psoriasis
The use of phototherapy  or sy stemic antipsoriatic medications is not permitted at any time during 
the study . These medications include those targeted for reducing tumor necrosis factor α
(including but not limited to infliximab , adalimumab, or etanercept), drugs targeted for reducing 
IL-12, IL-17A,IL-17R, or IL-23 (including but not limited to ustekinumab, tildrakizumab 
[MK3222], risankizumab [BI-655066], ixekizumab [LY2439821], or brodalumab [AMG827]), 
alpha -4 integrin antagonists (including but not limited to natalizumab), apremilast, steroids, any 
conventional systemic therapy  that could affect psoriasis or the IGA evaluation (including but 
not limited to MTX, cy closporine, acitretin), herbal treatments, or traditional Taiwanese, Korean, 
orChinese medicines, and any other biological agent or other systemic medication that could 
affect psoriasis or the IGA evaluation.
8.1.2. Concomitant Medications for Conditions Other than Psoriasis
Every  effort should be made to keep subjects on stable concomitan t medications. If the 
medication is temporarily  discontinued because of abnormal laboratory values, side effects, 
concurrent illness, or the performance of a procedure, the change and reason for it should be 
clearl y documented in the subject’s medical reco rd.
The use of stable doses of nonsteroidal anti-inflammatory  drugs is allowed. However, 
disease -modify ing agents such as MTX, sulfasalazine, or IM gold are prohibited during the 
study . Lithium and a ntimalarial agents may  not be used.
The use of corticosteroids for indications other than psoriasis should be limited to situations for 
which, in the opi[INVESTIGATOR_863344], there are no adequate alternatives. They  should be 
used on a short -term basis, preferably  for ≤2 weeks. L ongerterm use of corticosteroids should be 
discussed with the medical monitor or designee and may require discontinuation of study  drug. 
Inhaled, otic, ocular, nasal or other routes of mucosal delivery  of corticosteroids are allowed 
throughout the stud y.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , biomarker, and
safet ymeasurements applicable to this study .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
38
Approved , Date: 5 October 2017Investigator -reported efficacy  assessments (ie, IGA and PASI ) should be completed before any 
study  drug administrations, will be performed by [CONTACT_863368] ,and 
captured electronicall y on a tablet device at the appropriate visits, as outlined in the Time and 
Events Schedule.
A urine pregnancy  test will be performed to confirm the absence of pregnancy  at every  study 
drug administration visit.Additional urine pregnancy  tests may be performed, as determined 
necessary  by [CONTACT_31837], to establish the absence of 
pregnancy  at any  time during the subject's participation in the study .
The total blood volume to be collected from each subject will be approximately  189.5mL. In 
addition, repeat or unscheduled samples may be collected for safet y reasons or for technical 
issues with the samples.
9.1.2. Screening Phase
All subjects will have a screening visit that will occur approximately 4 weeks before their 
Week 0 visit. The screening phase is designed to assess inclusion/exclusion criteria and establish 
baseline characteristics f or a subject's psoriasis.
The recording of AEs and concomitant medications will start after the signing of the informed 
consent and will continue until the last study -related procedure has been completed. The eC-
SSRS (‘Baseline/Screening’ version) should be completed after the subject signs consent but as 
the first assessment by [CONTACT_863361], procedures, or other consultations to prevent 
influencing subject perceptions.
Each subject will be asked to sign the consent form at the screening vis it before an y stud y-related 
procedures are conducted.
The recording of AEs and concomitant medications will start after the signing of the informed 
consent and will continue until the last study -related procedure has been completed.
As outlined in the eligibility  criteria, all subjects must be questioned about a history  of TB or 
other personal exposure to individuals with active TB. Potential subjects should be asked about 
past testing for TB, including chest radiograph results and responses to tuberculin skin or other 
TB testing. With the exception of subjects with a history  of appropriately  treated latent TB 
within 5years before the first administration of study  drug (Inclusion Criterion 12 ), subjects 
must undergo testing for TB (seeAttachment 3orAttachment 4) and their medical history 
assessment must include specific questions about a history  of TB or known occupational or other 
personal exposure to individuals with active TB. The subject should be asked about past testing 
for TB, including chest radiograph results and responses to tuberculin skin or other TB testing.
Investigators have the option to use both the QuantiFERON -TB Gold test and the tuberculin skin 
test toscreen for latent TB if they believe, based on their judgment, that the use of both tests is 
clinically  indicated in order to evaluate a subject who has high risk of having latent TB. If either 
the QuantiFERON -TB Gold test or the tuberculin skin test is positive, the subject is considered 
to have latent TB infection for the purposes of eligibility  for this study .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
39
Approved , Date: [ADDRESS_1203973] result (and a negative tuberculin skin test 
result in countries in which the QuantiFERON -TB Gold test is not approved/ registered or the 
tuberculin skin test is mandated by [CONTACT_72952]) are eligible to continue with 
prerandomization procedures. Subjects with a newly  identified positive QuantiFERON -TB Gold 
or tuberculin skin test result must undergo an evaluation to rule out active TB and initiate 
appropriate treatment for latent TB. Appropriate treatment for latent TB is defined according to 
local country  guidelines for immunocompromised patients. If no local country  guidelines for 
immuno compromised patients exist, US guidelines must be followed, or the subject will be 
excluded from the study .
A subject whose first QuantiFERON -TB Gold test result is indeterminate should have the test 
repeated. In the event that the second QuantiFERON -TB Gold test result is also indeterminate, 
the subject should be excluded from the study .
Subjects will undergo screening for HBV (see Attachment 5 ) and antibodies to HCV and HIV.
9.1.3. Screen Failure/Rescreening
If, during the screeni ng phase, the subject has not met all inclusion criteria or met any exclusion 
criteria, or is unable or unwilling to adhere to the prohibitions and restrictions of the study , the 
subject is considered to be a screen failure and is not eligible to be random ized at that time.
In general, if the subject is a screen failure, but at some timepoint in the future meets all the 
subject eligibility  criteria, the subject may be rescreened after a new informed consent has been 
obtained. Subjects who are rescreened will be assigned a new subject number and will restart a 
new screening phase. Rescreening will be permitted once.
9.1.4. Double -Blind Treatment Phase
Week 0/Randomization
At Week 0, subjects who meet all inclusion criteria and do not demonstrate any  exclusion criteria 
will be randomized.
Randomization visit procedures will be performed as specified on the Time and Events Schedule. 
The ‘Since Last Visit’ version of the eC-SSRS questionnaire should be completed by [CONTACT_863369], procedures, or other consultations to prevent influencing subject 
perceptions (Section 9.6.1 )and to confirm eligibility . After completion of required study 
procedures, subjects will be administer ed study  drug according to their randomization 
assignment (guselkumab andplacebo or secukinumab ).
At Week 0, if a mental health evaluation is required based on the Week [ADDRESS_1203974] should be 
screen -failed and then re -screened after a completed mental health evaluation, if appropriate (see 
Section 9.6.1 ).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
40
Approved , Date: 5 October 2017Week 1 through Week 4 4
All visit procedures will be performed as specified in the Time and Events Schedule . The ‘Since 
Last Visit’ version of the eC-SSRS should be completed by [CONTACT_863370], 
procedures, or other consultations at postbaseline study  visits to prevent influencing subject 
perceptions (Section 9.6.1 )and to assess for potential discontinuation requirements. All other 
study  procedures and evaluations should be completed before the subject is administered study  
drug.
9.1.5. Posttreatment Phase (Follow -Up)
Subjects will be followed for efficacy , safet y, and biomarker information throug h Week 56 as 
shown in the Time and Events Schedule. The ‘Since Last Visit’ version of the eC-SSRS should 
be completed by [CONTACT_863370], procedures, or other consultations at the 
follow -up visit to prevent influencing subject perceptions (Section 9.6.1 ). Subjects will be 
instructed that study  drug will not be made available to them after they have 
completed/discontinued study  drug and that they should return to their primary  physician to 
determine subsequent treatment of their psoriasis.
9.2. Efficacy Evaluations
9.2.1. Evaluations
Efficacy  evaluations chosen for this study  are consistent with those utilized to evaluate other 
therapi[INVESTIGATOR_109006]. Efficacy  evaluations include:
IGA
PASI
Efficacy assessments (IGA, PASI )will be performed at the site by [CONTACT_863371] a tablet device at the appropriate visits as outlined 
by [CONTACT_863372] .The sponsor will provide IGA and PASI  training. 
Documentation of this training will be maintained in the site’s training files and by [CONTACT_456].
[IP_ADDRESS]. Investigator’s Global A ssessment
The IGA documents the investigator’s assessment of the subject’s psoriasis at a given timepoint
(Attachment 1). Overall lesions are graded for induration, erythema, and scaling. The patient’s 
psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).A higher 
score i ndicates more severe disease.
[IP_ADDRESS]. Psoriasis A rea and Severity Index
The PASI  is a system used for assessing and grading the severit y of psoriatic lesions and their 
response to therapy  (Attachment 2).5In the PASI system, the body  is divided into 4 regions: the 
head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separatel y 
for the percentag e of the area involved, which translates to a numeric score that ranges from 0 
(indicates no involvement) to 6(90% -100% involvement), and for erythema, induration, and 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
41
Approved , Date: 5 October 2017scaling, which are each rated on a scale of 0to 4. The PASI  produces a numeric score that could 
range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
9.3. Pharmacokinetics and Immunogenicity
Serum samples will be analy zed to determine guselkumab concentrations and antibodies to 
guselkumab according to the Time and Events Schedule. Additionally , serum samples should be 
collected at the final visit from subjects who are withdrawn from the stud y.
Serum samples that test positive for antibodies to guselkumab will be further characterized to 
determine if antibodies to guselkumab could neutralize the biological effects of guselkumab in 
vitro (ie, neutralizing antibodies to guselkumab).
All sample anal yses will be conducted b y the sponsor or sponsor's designee.
9.4. Biomarkers
Biomarker sample collections will be conducted at the timepoint s presented in the Time and 
Events Schedule to measure serum markers, gene expression and cellular profiles in skin 
biopsies,  and genetic associations 
with psoriasis or response to treatment (each explained in detail below). Data collected from 
these samples will be used for exploratory  research that will include the following objectives:
1.To understand the molecular effects of guselkum ab and secukinumab.
2.To understand psoriasis pathogenesis.
3.To understand wh y individuals differ in their responses to guselkumab or secukinumab.
4.  
Instructions for the collection and shipment of these samples can be found in the appropriate 
Laboratory  Manual.
Serum Biomarkers
Serum samples will be collected from all subjects according to the Time and Events Schedule. 
These samples will be analyzed for the presence of serum biomarkers related to psoriasis, 
inflammation, and/or any observable PDrelationship with either guselkumab or secukinumab 
response to treatment . Measurements will include but are not limited to serum IL-17A, IL-17F 
and IL -22 levels.
Skin Biopsy (RNA and Histology)
Skin biopsy  samples will be collected according to the Time and Events Schedule from a subset 
of subjects who consent to participate in the biopsy  substudy (target n = 45 per group, at 
predefined study  sites capable of performing the skin biopsy  procedure) . Enrollment will be 
optional at selected predefined sites. Consenting subjects will undergo collection of skin biopsies 
which will be used for assessment of RNA expression, T cell receptor repertoire assessment, 
histology , epi[INVESTIGATOR_863345], and immunohistochemistry .Psoriasis pathogenesis involves the 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
42
Approved , Date: [ADDRESS_1203975]-treatment, including potential evaluation of specific immune cell subsets 
such as Th17 and regulatory  T (Treg) cells. Skin samples will also be processed for RNA 
transcriptional profiling to determ ine gene expression profile changes associated with response 
to guselkumab or secukinumab. Evaluation may also be conducted on skin samples to assess 
epi[INVESTIGATOR_863346].
 
 
 
 
 
 
 
9.5. Genetic (DNA ) Analysis
Genetic (DNA) research may consist of the analy sis of one or more candidate genes ,single 
nucleotide polymorphisms, or analysis of the entire genome (as appropriate) in relation to 
guselkumab, secukinumab or psoriasis clinical endpoints. Whole blood samples of 
approximately  12 mL will be collected for genetic analyses at a single timepoint as specified in 
the Time and Events Schedule. Epi[INVESTIGATOR_863347]. Only  subjects who sign the consent 
form to participate in the genetic (DNA) assessment will have whole blood DNA or skin samples 
collected.
9.6. Safety  Evaluations
The safet y and tolerability  of study  drugs (guselkumab, secukinumab , or placebo, where 
appropriate ) will be monitored by [CONTACT_863373], including injection site and 
allergic reactions, clinical laboratory  tests, physical examinations, vital signs, eC-SSRS
questionnaires, electrocardiograms (ECGs), concomitant medication review, and early detection 
of TB, as specifi ed in the Time and Events Schedule. Serum and/or plasma samples collected for 
biomarker analyses may also be used to evaluate safet y concerns that may arise during or after 
the study  period.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
43
Approved , Date: [ADDRESS_1203976] be recorded on the AEsection of the eCRF.
Clinically  important abnormalities persisting at the end of the study /early  withdrawal may be 
followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the 
timepoint s provided in the Time and Events Schedule:
Adverse Events
Adverse events will be reported by [CONTACT_214442] . Adverse events will 
be followed b y the investigator as specified in Section 12, Adverse Event Reporting .
Early Detection of Active Tuberculosis
To aid in the early  detection of TB reactivation or new TB infection during study  participation, 
subjects must be evaluated for signs and symptoms of active TB at scheduled visits (refer to 
Time and Events Schedule) or by [CONTACT_41021] 8  to 12 weeks. The 
following series of questions is suggested for use during the evaluation:
“Have you had a new cough of >14 days’ duration or a change in a chronic cough?”
“Have you had an y of the following s ymptoms:
Persistent fever ?
Unintentional weight loss?
Night sweats?”
“Have you had close contact [CONTACT_41022]?” (If there is uncertaint y as 
to whether a contact [CONTACT_41023] “close,” a physician specializing in TB should be 
consulted.)
If the evaluation raises suspi[INVESTIGATOR_40958] a subject may have TB reactivation or new TB infection, 
an immediate and thorough investigation should be undertaken, including, where possible, 
consultation with a phy sician specializing in TB.
Investigators should be aware that TB reactivation in immunocompromised subjects may  present 
as disseminated disease or with extrapulmonary  features. Subjects with evidence of active TB 
should be referred for appropriate treatment.
Subjects who experience close contact [CONTACT_402558] a repeat chest radiograph, a repeat QuantiFERON -TB Gold test, a repeat 
tuberculin skin test in countries in which the QuantiFERON -TB Gold test is not 
approved/registered or the tuberculin skin test is mandated by [CONTACT_72952], and, if 
possible, referral to a physician specializing in TB to determine the subject’s risk of developi[INVESTIGATOR_863348].
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
44
Approved , Date: [ADDRESS_1203977] immediately  discontinue further administration of study  drug and be encouraged to 
return for all subsequent scheduled stud y visits according to the Time and Events Schedule.
Allergic Reactions
The sponsor will proactively  monitor reported AEs and query  the site, if necessary , to capture 
anaph ylactic reaction/serum sickness events in eCRFs.
Injection Site Reactions
An injection site reaction is any unfavorable or unintended sign that occurs at the study  drug 
injection site. After administration of study  drug at Week 0, all subjects will be carefully 
observed at the study  site for at least [ADDRESS_1203978] should 
be treated at the investigator’s discretion. Any adverse reaction (eg, pain, erythema, and/or 
induration) should be noted on the AEpage of the eCRF.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology  will be collected. The investigator must 
review the laboratory  results, document this review, and record any clinically  relevant changes 
occurring during the study  in the AEsection of the eCRF. The laboratory reports must be filed 
with the source documents.
All abnormal laboratory  values will be evaluated for clinical significance by [CONTACT_093]. If 
clinically  significant abnormal laboratory  values (in the opi[INVESTIGATOR_35272]) are detected, 
then the test(s) should be repeated until they return to normal or are otherwise explained by [CONTACT_3786].
Instructions for the collection, handling, and shippi[INVESTIGATOR_863349].
The follow ing tests will be performed by  [CONTACT_2237] :
Hematology  Panel
-hemoglobin -neutrophils
-hematocrit -bands
-red blood cell count -eosinophils
-white blood cell count -basophils
-lymphocy tes -platelets
-monocy tes
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
45
Approved , Date: 5 October 2017Serum Chemistry  Panel
-sodium -calcium
-potassium -albumin
-chloride -total protein
-alkaline phosphatase -alanine aminotransferase
-urea -total carbon dioxide
-creatinine -total bilirubin
-glucose -high-sensitivity  C-reactive protein
-aspartate aminotransferase -follicle -stimulating hormonea
aTesting required for selected subjects as defined in Inclusion Criterion 8.
Lipid Panela
-total cholesterol -total cholesterol to high density  lipoprotein 
cholesterol ratio
-low density  lipoprotein cholesterol -triglycerides
-high densit y lipoprotein cholesterol
a(Week 0 only; subjects must fast (ie, no food or beverages [except w ater]) for at least 8 hours before blood is 
draw n for lipid panel)
Serology : HBV, including HBV serology  and HBV DNA (when indica ted, see 
Attachment 5), and antibodies to HCV and HIV.
Pregnancy Testing
Urine pregnancy  testing is required for all women of childbearing potential at all study  visits
with study  agent administration and at other visits as specified in the Time and Events Schedule .
Pregnancy  tests must be completed and negative at the study  visit prior to administration of study  
drug. All pregnancy  test results must be recorded in study  source documents.
Physical Examination
Physical examina tions will be performed by [CONTACT_247912], nurse 
practitioner or physician assistant as specified in the Time and Events Schedule s. Any new, 
clinically  significant finding (in the opi[INVESTIGATOR_871]) must be captured as an AE. In 
addition, resolution of any abnormal findings during the study  will be noted in the source 
document and in the eCRF.
Height and Weight
Height and weight will be measured as specified in the Time and Events Schedule. Subjects will 
be instructed to remove shoes and outdoor apparel and gear prior to these measurements.
Vital Signs
Blood pressure and heart rate measurements will be assessed at the timepoint s specified in the 
Time and Events Schedule. If any clinically  significant changes in vital signs are noted, they 
must be reported as AEs and followed to resolution, or until reaching a clinically  stable endpoint.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
46
Approved , Date: 5 October 2017Electrocardiogram
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supi[INVESTIGATOR_21683] 5minutes before 
ECG collection and should refrain from talking or moving arms or legs. If blood sampling or 
vital sign measurement is scheduled for the same timepoint as ECG recording, the procedures 
should be performed in the following order: ECG(s), vital signs, blood draw.
9.6.1. Electronic Columbia -Suicide Severity  Rating Scale
In light of the recent reports concerning suicidal ideation and behavior in patients with plaque 
psoriasis treated with an IL-17R antagonist (brodalumab),3the eC-SSRS will be used as a 
screening tool to prospectively  evaluat e the potential of guselkumab to induce suicidal ideation 
and behavior. The eC-SSRS defines 5subty pes of suicidal ideation and behavior in addition to 
self-injurious behavior with no suicidal intent, and is a fully-structured, subject self-report 
C-SSRS questionnaire, including standardized questions, follow -up prompts, error handling 
routines, and scoring conventions.10,15Two versions of the eC-SSRS will be used in this study , 
the ‘Baseline/Screening’ version and the ‘Since Last Visit’ version. The ‘Baseline/Screening’ 
version of the eC-SSRS will be conducted during the screening visit followed by [CONTACT_941] ‘Since Last 
Visit’ version of the eC -SSRS at Week 0, and all visits starting at Week [ADDRESS_1203979] at the screening visit (after 
signing informed consent) and before study  agent administration. At all postbaseline visits, the 
eC-SSRS will be the first assessment/ questionnaire that the subject must complete.
At the conclusion of each assessment, the site will receive an eC-SSRS Findings Report. At 
screening and Week 0, subjects with an eC-SSRS score greater than 0 or a response to the 
question of “Self -injurious be havior without suicidal intent” other than ‘NO’ must be determined 
to be not at risk by [CONTACT_356327] a mental health professional in 
order to be randomized. Subjects with a score on the eC -SSRS that is greater than 0 or a resp onse 
to the question of “Self -injurious behavior without suicidal intent” other than ‘NO’ at any post-
baseline visit will also be referred to an appropriate mental health professional for evaluation. If 
the subject’s psychiatric disorder can be adequatel y treated with psychotherap y and/or 
pharmacotherap y then the subject, at the discretion of the investigator, should be continued with 
treatment. Ultimatel y, the determination of suicidality  and risk is up to the investigator’s clinical 
judgment following evaluation by a mental health professional (eg, psychiatrist, psychologist, or 
appropriatel y trained social worker or nurse).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
47
Approved , Date: 5 October 2017Positive reports are generated from the eC -SSRS vendor for ANY of the following findings:
Suicidal ideation with intention to act (“4 ”)
Suicidal ideation with specific plan and intent (“5”)
Made suicide attempt
Interrupted suicide attempt
Aborted suicide attempt
Preparatory behaviors for making a suicide attempt.
Negative suicidality  indication reports are generated from the eC-SSRS vendor when there are 
NO indications of the above.
The subject should not be released from the site until the eC-SSRS Findings Report (both for 
negative and positive reports) is reviewed by [CONTACT_27379]’s risk has been 
assessed and follow- up determined, as appropriate.
For each score, the following actions and associated alerts will be generated, if applicable:
Score of 0: No further action is needed.
Score > 0: Subject risk assessed and referral to a mental health professional.
Score of 1, 2, or 3: Negative findings report will be generated.
Score of 4 or higher: Positive findings report will be generated. When the system 
reports that the subject has a positive suicidal indication (including for an incomplete 
assessment), the site will be immediately  notified by [CONTACT_6791]/email and a telephone call 
from the eC -SSRS vendor.
Self-injurious behavior without suicidal intent = YES or ‘Question Mark (ambiguous 
response)’: Subject risk assessed and referral to a mental health professional. Negative 
findings report will be generated.
Interruption or the discontinuation of study  treatment should be considered for any subject who 
reports suicidal ideation with intention to act (“4”), suicidal ideation with specific plan and intent 
(“5”), or a suicide attempt (interrupted suicide attempt, aborted suicide attempt, or preparatory  
behaviors for making a suicide attempt) on a post-baseline eC-SSRS assessment and who is 
deemed to be at risk by [CONTACT_863374] a mental health professional. 
Discussion of such subjects with the medical monitor or designee is required (See Section 10.2). 
The final decision on suitability  for continuing in the study will be made by [CONTACT_093].
Any eC-SSRS finding, which in the opi[INVESTIGATOR_356306] a 
worsening and clinically  significant, should be reported on the AE eCRF (see Section 12).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
48
Approved , Date: [ADDRESS_1203980] COMPLETION/ DISCONTINUA TION OF STUDY TREATMENT/ 
WITHDRA WALFROM THE S TUDY
10.1. Completion
A subject will be considered to have completed the study  if he or she has completed assessments 
at Week 56of the double -blind phase. Subjects who prematurel y discontinue study  treatment for 
any reason before completion of the double -blind phase will not be considered to have completed 
the study .
10.2. Discontinuation of Study Treatment /Withdrawal from the Study
Discontinuation of Study Treatment
A subject will not be automatically  withdrawn from the study  if he or shehasto discontinue 
treatment before the end of the treatment regimen.
A subject's study  treatment must bediscontinue d if:
The investigator believes that for safety  reasons or tolerability  reasons (eg,AE) it is in the 
best interest of the subject to discontinue study treatment
The s ubject becomes pregnant
The subject is diagnosed with a malignancy , with the exception of no more than 2 localized 
basal cell skin cancers that are treated with no evidence of recurrence or residual disease.
The subject is deemed ineligible according to th e following TB screening criteria:
A diagnosis of active TB is made.
A subject has symptoms suggestive of active TB based on follow -up assessment 
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a person 
with active TB , and canno t or will not continue to undergo additional evaluation.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
49
Approved , Date: 5 October 2017A subject undergoing evaluation has a chest radiograph with evidence of current active 
TB and/or a positive QuantiFERON -TB Gold test result and/or an indeterminate 
QuantiFERON -TB Gold test result on repeat testing (refer to Section 9.6) (and/or a 
positive tuberculin skin test result in countries in which the QuantiFERON -TB Gold test 
is not approved/registered or the tuberculin skin test is mandated by [CONTACT_405737]). Indeterminate QuantiFERON -TB Gold test results should be handled as 
described in Section 9.6.
A subject receiving treatment for latent TB discontinues this treatment prematurely  or is 
noncompliant with the therap y.
The subject initiates a protocol -prohibited medication, eg, for a worsening of his or her 
psoriasis (unless agreed to by  [CONTACT_7195]).
The subject withdraws consent for administration of study  drug.
The subject is unable to adhere to the study  visit schedule or comply  with protocol 
requirements.
The subject develops an allergic reaction such as bronchospasm with wheezing and/or 
dyspnea requiring ventilatory  support, or symptomatic hypotension that occurs following a 
study  drug administration.
The subje ct has a reaction resulting in myalgia and/or arthralgia with fever and/or rash 
(suggestive of serum sickness and not representative of signs and symptoms of other 
recognized clinical syndromes) occurring 1 to 14 days after an injection of study  drug. Thes e 
may be accompanied by [CONTACT_41024], facial, hand, or lip edema, 
dysphagia, urticaria, sore throat, and/or headache.
Discontinuation of study  treatment should be considered for subjects who report suicidal 
ideation with intention to act(“4”), suicidal ideation with specific plan and intent (“5”), or a 
suicide attempt (interrupted suicide attempt, aborted suicide attempt, or preparatory 
behaviors for making a suicide attempt) on a postbaseline eCSSRS assessment. Discussion 
of such subje cts with the medical monitor or designee is required.
Discontinuation of study  treatment should be considered for subjects who develop a serious 
or opportunistic infection. Discussion of such subjects with the medical monitor or designee 
should also be con sidered.
Subjects who decide to discontinue study  drug administration must be interviewed by [CONTACT_863375] a specific reason for discontinuing study  drug can be identified. 
Subjects should be explicitly  asked about the possible contribut ion of AEsto their decision to 
discontinue study  drug; investigators should confirm that any AEinformation elicited has been 
documented. If the subject elects to discontinue study  drug due to an AE, the event should be 
recorded as the reason for study  drug discontinuation, even if the investigator ’s assessment is 
that the AE would not require study  drug discontinuation. The reason for study  drug 
discontinuation must be documented in the eCRF and in source documents. Study  drug assigned 
to a subject who di scontinues may  not be assigned to another subject.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
50
Approved , Date: [ADDRESS_1203981] will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
To ensure access for subject follow -up, study sites should try to obtain both primary  and 
secondary  telephone contact [CONTACT_863376] (eg, home, work, and mobile phones), as 
well as other contact [CONTACT_356334], and emphasize the importance of 
follow -up information to the subject, before randomization . For subjects who withdraw from 
study  participation, every  effort should be made to conduct the Week [ADDRESS_1203982] fails to return for study  visits (and thus is considered lost to follow -up), study  site 
personnel must make all reasonable efforts to contact [CONTACT_863377]’s 
reason for discontinuation/withdrawal before considering the subject to be lost to follow -up. 
Such efforts should include repeated telephone calls, certified letters, email requests, etc. 
Measures taken to obtain follow -up information must be documented.
Withdrawal of consent should be a very unusual occurrence in a clinical trial; the investigator 
should make e very effort to maintain good subject relationships to avoid withdrawals of consent. 
For subjects who truly request withdrawal of consent, it is recommended that the subject 
withdraw consent in writing; if the subject or the subject’s representative refuses to do so or is 
physicall y unavailable, the study  site should document the reason for the subject’s failure to 
withdraw consent in writing, sign the documentation, and maintain it with the subject’s source 
records. When a subject withdraws before completin g the study , the reason for withdrawal is to 
be documented in the eCRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not be replaced.
10.3. Withdrawal From the Use of Research Samples
A subject who withdraws from the study  will have the following options regarding the optional
research samples :
The collected samples will be retained and used in accordance with the subject's original 
separate informed consent for optional research samples.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
51
Approved , Date: 5 October 2017The subject may withdraw consent for optional research samples, in which case the sample s
will be destroy ed and no further testing will take place. To initiate the sample destruction 
process, the investigator must notify  the sponsor study  site contact [CONTACT_244538]. The sponsor study  site 
contact [INVESTIGATOR_1318], in turn, contact [CONTACT_90805]. If 
requested, the investigato r will receive written confirmation from the sponsor that the 
sample shave been destroy ed.
Withdrawal From the Optional Research Samples While Remaining in the Main Study
The subject may  withdraw consent for optional research samples while remaining in the study . In 
such a case, the optional research samples will be destroy ed. The sample destruction process will 
proceed as described above.
Withdrawal From the Use of Sample s in Future Research
The subject may  withdraw consent for use of sample sfor research ( refer to Section 16.2.5 , Long-
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroyed after they are no longer needed for the clinical study . Details of the sample retention
for research are presented in the main ICF and in the separate ICF for optional research samples.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan (SAP) .
Descriptive statist ics will include counts and proportions for categorical data, and median, mean, 
interquartile range, and range for continuous data. Graphical data display s may also be used to
summarize the data.
In order to compare the proportion of subjects responding tothe two treatments, the Cochran -
Mantel -Haenszel chi-square test stratified by [CONTACT_863360]. To test the non-
inferiority  of guselkumab to secukinumab , a 1-sided (α=0.025) Z-testwith Mantel -Haenszel 
weights adjusted by [CONTACT_863360] . A longitudinal modeling approach willalso be 
used as a sensitivity  analysisto compare the proportion of subjects responding to treatment. All 
statistical testing will be performed 2-sided at a significance level of 0.05 for superiority  and 
1-sided at a significance level of 0.025 for non- inferiority .
Subjects who discontinue study  agent due to lack of efficacy  or an AEof worsening of psoriasis, 
or who started a protocol -prohibited medication/therap y during the study  that could improve 
psoria sis are considered treatment failures. The baseline values will be assigned regardless of the 
observed data for continuous endpoints, zero will be assigned to improvement and percent 
improvement, and nonresponder status will be assigned to binary  response variables. After 
apply ing the treatment failure rules, the remaining missing data will be assigned nonresponder 
status for binary  variables. For the longitudinal analy ses, treatment failure rules or missing data 
handling rules will not be applied.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
52
Approved , Date: [ADDRESS_1203983] 1 dose (complete or partial) of 
study  medication, will also be used for PK, immunogenicity , andsafet y analyses by [CONTACT_84774].
Descri ptive statistics by [CONTACT_863378], demographics, baseline disease characteristics, 
and prior and concomitant medications. Details will be provided in th e SAP.
11.2. Sample Size Determination
This study  is designed to evaluate the efficacy  of guselkumab 100 mg vs secukinumab 300 mg. 
The assumptions for the sample size and power calculations were based on the data from the 
guselkumab CNTO1959PSO3001 and CNTO1959P SO3002 and the secukinumab Phase 3 
studies (ERASURE and FIXTURE). The assumptions used are as follows:
The proportion of subjects who achieve a PASI  90response at Week 48is70% to 80% in 
subjects receiving guselkumab and 60 %to70% for subjects receiving secukimumab.
The proportion of subjects who achieve a PASI  100response at Week 48is44% to 51% in 
subjects receiving guselkumab and 35 %to 40% for subjects receiving secukimumab.
Approximately  1,040 subjects are planned to be randomized in a 1:1 ratio to either guselkumab 
100 mg (n=520) ( administered at Weeks 0, 4, 12 and q8w thereafter until Week 44)or 
secukinumab 300 mg (n=520) (administered at Weeks 0, 1, 2, 3 , and4 and q4w there after until 
Week 44).
Based on the above assumptions ,the planned sample size,and a noninferiority  margin of 10%, 
the power to demonstrate the non-inferiority  for the primary  endpoint of PASI  90 at Week 48 
and the major secondary  endpoint of PASI  100 at Week 48 will be > 99%.
Table 1provides the power for detecting a treatment difference (superiority  of guselkumab over 
secukinumab) under varying assumptions at a significance level of 0.[ADDRESS_1203984] major secondary  endpoint of PASI 100 at Week 48 specified 
in Section 2.1.2 .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
53
Approved , Date: 5 October 2017Table 1: Power to D etect a Treatm ent Effect B ased on Different Proportions of Subjects Achieving the 
Primary Endpoint PASI 90 at Week 48 and the Major Secondary Endpoint PASI 100 at 
Week 48
Primary Endpoint
PASI 90 at Week 48
Secukinumab 300 mg (n=520) Guselkumab 100 mg (n=520 )
60% 70% 92%
75% >99%
65% 75% 94%
80% >99%
70% 80% 96%
Selected Major Secondary Endpoint
PASI 100 at Week 48
35% 44% 84%
45% 91%
46% 95%
40% 49% 83%
50% 90%
51% 95%
PASI = Psoriasis Area and Severity Index.
11.3. Efficacy  Analyses
11.3.1. Analysis Data Set
For the primary  analysis and major secondary  analyses, all randomized and treated subjects will 
be included. For all the efficacy  analyses, subjects will be analy zed according to the treatment 
group to which they  arerandomized, regardless of the treatment they  actually  receive.
11.3.2. Primary  Analysis
The primary  endpoint in this study  is the proportion of subjects who achieve a PASI [ADDRESS_1203985]. 
The following stepwise comparisons will be made to compare the efficacy  of guselkumab to that 
of secukinumab at Week 48:
a.A non-inferiorit y margin of 10% was chosen based on a minimally  clinically  meaningful 
difference .This margin was also used as the non-inferiorit y margin for the ustekinum ab
psoriasis study C0743T12 and the guselkumab psoriasis CNTO1959PSO3001 and 
CNTO1959PSO3002 studies. To claim the non-inferiorit y of guselkumab over 
secukinumab, the lower bound of the 2- sided 95% c onfidence interval of P1 –P2 must be 
≥ –10%, where P1 and P2 are the proportions of subjects achieving a PASI [ADDRESS_1203986] will be conducted and Step b will be skipped.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
54
Approved , Date: [ADDRESS_1203987] of guselkumab to 
secukinumab will be performed at 2- sided (α=0.05).
If both the non-inferiority  test and the superiority  test are positive, the major secondary 
hypotheses comparing the guselkumab group and the secukinumab group will be tested
sequentially . Otherwise, all remaining p -values will be considered nominal.
11.3.3. Major Secondary  Analyses
For the major secondary analysis, all non-inferiority  tests will be performed 1-sided (α=0.025) 
with a non- inferiorit y margin of 10% .The major secondary  anal yses are:
The non-inferiorit y test comparing guselkumab with secukinumab for the proportio n of 
subjects achieving a PASI  75response at both Week [ADDRESS_1203988] on this endpoint will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI 90 response at Week 12 will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI 75 response at Week 12 will be performed.
The non-inferiorit y testcomparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI  [ADDRESS_1203989] on this endpoint will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving an IGA score of cleared (0) at Week [ADDRESS_1203990] on this endpoint will be performed.
[IP_ADDRESS]. Multiplicity  Control
In order to control the overall Type [ADDRESS_1203991] major secondary 
analysiswill be performed only if the primary  endpoint is positive for both non-inferiority  and 
superiority , and the subsequent analy siswill be performed only if the preceding analy sisin the 
sequence is positive.
11.3.4. Other Efficacy  Analyses
In addition to the primary  and major secondary  analyses, the analyses for other efficacy 
endpoints will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI  90response at both Week 16and Week [ADDRESS_1203992] on this endpoint will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI 75 response at Week 16 will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI 90 response at Week 16 will be performed.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
55
Approved , Date: 5 October 2017The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving a PASI [ADDRESS_1203993] on this endpoint will be 
performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving an IGA score of cleared (0) or minimal (1) at Week 16 will be performed.
The non-inferiorit y test comparing guselkumab with secukinumab for the proportion of 
subjects achieving an IGA score of cleared (0) or minimal (1) at Week 12 will be performed.
The proportions of subjects who achieve a PASI 75 response at Week 48 among PASI 75 
responders at Week 12 will be summarized by  [CONTACT_1570].
The proportions of subjects who achieve a PASI 90 response at Week 48 among PASI 90 
responders at Week 16 will be summarized by  [CONTACT_1570].
The proportions of subjects who achieve a PASI  50/75 /90/100 response over time through 
Week 48 will be summarized by  [CONTACT_1570].
The proportions of subjects who achieve anIGA score of cleared (0) response, IGA score of 
cleared (0) or minimal (1) response , and IGA of cleared (0), minimal (1), or mild (2)
response over time through Week 48 will be summarized by  [CONTACT_1570] .
The percent ages ofimprovement in PASI  over time through Week 48will be summarized 
by [CONTACT_1570].
Furthermore, subgroup analyses will be performed to evaluate consistency  of the primary 
endpoint and select major secondary  endpoints over demographics (including baseline weight),
baseline disease characteristics and prior medications. Additional efficacy  analyses may be 
performed and will be documented in the SAP.
11.4. Criteria for Endpoints
PASI  50 Responders : Subjects with ≥50% improvement in PASI  from baseline.
PASI  75 Responders : Subjects with ≥75% improvement in PASI  from baseline.
PASI  90 Responders : Subjects with ≥90% improvement in PASI  from baseline.
PASI  100 Responders: Subjects with 100% improvement in PASI from baseline.
11.5. Pharmacokinetic A nalyses
Serum guselkumab concentrations over time will be summarized for the guselkumab group. 
Descriptive statistics, including arithmetic mean, SD, median, interquartile range, minimum, and 
maximum will be calculated at each sampling timepoint. All concentrations below the lowest 
quantifiable sample concentration of the assay  (BQL) or missing data will be labeled as such in 
the concentration data listing or statistical analysis system (SAS) dataset. The BQL 
concentrations will be treated as zero in the summary  statistics.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
56
Approved , Date: [ADDRESS_1203994] appropriate samples for detection of antibodies to 
guselkumab (ie, subjects with at least [ADDRESS_1203995] dose of guselkumab). A 
listing of subjects who are positive for antibodies to guselkumab will be provided in the clinical 
study  report.
The incidence of neutralizing antibodies (NAbs) to guselkumab will be summarized for subjects 
who are positive for antibodies to guselkumab and have samples evaluable for NAbs.
11.7. Biomarker Analyses
Biomarker samples outlined in Section 9.4will be used to assess serum markers, skin gene 
expression and cellular profiles,  and genetic (DNA) data for 
biomarker anal yses. Biomarker analyses will add ress the following objectives:
1.To understand the molecular effects of guselkumab and secukinumab.
2.To understand psoriasis.
3.To understand wh y people may respond differently  to guselkumab and secukinumab.
4.  
These analy ses are considered exploratory  and will be summarized in a separate technical report.
Planned biomarker analy ses may be deferred if emerging study  data show no likelihood of 
providing useful scientific information.
Changes in serum/RNA or other biomarkers over time will be summarized by [CONTACT_1570]. 
Associations between baseline levels and changes from baseline in select biomarkers and clinical 
response will be explored. RNA anal yses will be summarized in separate technical reports.
Results will be presented in a separate report.
11.8. Safety  Analyses
Safety  data, including but not limited to, AEs, SAEs , infections, serious infec tions, changes in 
laboratory  assessments, changes in vital signs, changes in electrocardiograms (ECGs ),and 
suicidal ideation and behavior based on eC-SSRS will be summarized. Treatment -emergent AEs 
will be summarized by [CONTACT_863379] 
(MedDRA) s ystem organ class and preferred terms.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
57
Approved , Date: 5 October 2017Safety Definitions
Injection Site Reactions
An injection site reaction is any unfavorable or unintended sign that occurs at an injection site 
and will be recorded as an AE. Detailed instructions for the evaluation of injection site reactions 
are in the Trial Center File.
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_863380]. All reported AEs with onset during the treatm ent phase (ie, treatment -emergent AEs, 
and AEs that have worsened since baseline) will be included in the analy sis.
Summaries, listings, or subject narratives may be provided, as appropriate, for those subjects 
who die, who discontinue treatment due to an AE, or who experience a severe AEor anSAE .
The following anal yses will be used to assess the safet y of subjects in the study:
The incidence and t ype of AEs.
The incidence and t ype of SAE s.
The incidence and t ype of infections.
The incidence and t ype of r easonably  related AEs.
The incidence and t ype of injection site reactions.
The laboratory  parameters and change from baseline in laboratory  parameters (hematology 
and chemistry ).
In addition, National Cancer Institute -Common Terminology  Criteria for Advers e Events (NCI -
CTCAE) grades will be used in the summary  of laboratory  data. A listing of subjects with post-
baseline abnormal laboratory  results based on NCI -CTCAE grades will also be provided.
Vital Signs
Descriptive statistics of heart rate and blood pressure (systolic and diastolic) values and changes 
from baseline will be summarized by  [CONTACT_1570].
Electrocardiogram
Electrocardiogram data will be collected at baseline and Weeks 16 and 48. Electrocardiogram 
data at each visit and change from basel ine will be summarized by [CONTACT_863381] .
Electronic Columbia-Suicide Severity Rating Scale
Suicide -related thoughts and behaviors based on the eC-SSRS will be summarized descriptivel y 
by [CONTACT_1570].
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
58
Approved , Date: 5 October 2017Anticipated Events
An anticipated event is an AE(serious or non-serious) that commonly  occurs as a consequence 
of the underl ying disease or condition under investigation (disease related) or background 
regimen. For the purposes of this study  the event of psoriasis will be considered an anticipated 
event . Serious adverse event s relating to lack of efficacy  (eg, events attributed to “psoriasis”) or 
progression of the disease under study  will not be individually  unblinded for expedited reporting. 
These anticipated events will be recorded and reported as outlined in Attachment [ADDRESS_1203996] Operating Procedures in 
conformity  with regulatory  requirements worldw ide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with the treatment. An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investigational or non-investigational) produc t. (Definition per International 
Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF(refer to Section 12.3.[ADDRESS_1203997] AErecording).
Serious Adverse Event
AnSAE, based on ICH and European Union Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use, is any  untoward medical occurrence that at an y dose:
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
59
Approved , Date: 5 October 2017Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited re porting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AEis considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safety information. For guselkumab, the expectedness of an AEwill be 
determined by [CONTACT_83408]'s Brochure. For secukinumab the 
expectedness of an AE will be determined by [CONTACT_863382]/summary  of product characteristics.
Adverse Event Associated With the Use of the Drug
An AEis considered associated with the use of the drug if the attribution is possible, probable, or 
very likely  by [CONTACT_23826] 12.1.2 , Attribution Definitions .
12.1.2. Attribution Definitions
Not Related
An AEthat is not related to the use of the drug.
Doubtful
An AEfor which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
60
Approved , Date: 5 October 2017Possible
An AEthat might be due to the use of the drug. An alternative explanation, eg,concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AEthat might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_863383]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An AEthat is listed as a possible adverse reaction and cannot be reasonably  explained by [CONTACT_43767], eg, concomitant drug(s), conc omitant disease(s). The relationship in time 
is very  suggestive (eg, it is confirmed by  [CONTACT_35719]).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Accidental or occupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Special reporting situations should be recorded in the eCRF . Any special reporting situation that
meets the criteria of a nSAE should be recorded on the SAE page of the eCRF .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
61
Approved , Date: [ADDRESS_1203998]'s last study -related 
procedure ,which may include contact [CONTACT_20687] -up of safet y. Serious adverse events, including 
those spontaneousl y reported to the investigator within [ADDRESS_1203999] be 
recorded using medical terminology  in the source document and the eCRF . Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should bereported as "upper respi[INVESTIGATOR_28945]"). Investigators must record in the eCRF their opi[INVESTIGATOR_43715] y. All measures required for AEmanagement must be recorded in the 
source document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpe cted serious adverse reactions (S[LOCATION_003]Rs) . For anticipated 
events reported as individual SAEs the sponsor will make a determination of relatedness in 
addition to and independent of the investigator’s assessment. The sponsor will periodicall y 
evaluate the accumulating data and, when there is sufficient evidence and the sponsor has 
determined there is a reasonable possibility  that the drug caused a serious anticipated event, they 
will submit a safet y report in narrative format to the investigators (and the head of the
investigational institute where required ). The investigator (or sponsor where required) must 
report S[LOCATION_003]Rs to the appropriate Independent Ethics Committee/I nstitutional Review Board 
(IEC/I RB) that approved the protocol unless otherwise required and documented by [CONTACT_12137]/IRB .A S[LOCATION_003]R will be reported to regulatory  authorities unblinded. Participating 
investigators and IEC/I RB will receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
Serious adverse events relating to lack of efficacy  (eg, events attributed to “psoriasis”) or 
progression of the disease under study  will not be individually  unblinded for expedited reporting. 
These anticipated events will be recorded and reported as described in Attachment 6. All SAEs 
and nonserious AEs that represent any of the following diagnoses or any symptoms associated 
with the following diagnoses (eg, chest pain, dizziness) must be reported to the sponsor and will 
require efforts to obtain additional medical records:
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
62
Approved , Date: 5 October 2017Myocardia l infarction .
Stroke.
Cardiovascular death .
Unstable angina .
Coronary  revascularization (percutaneous coronary  intervention or coronary  artery  by[CONTACT_101874] ).
Transient ischemic attack .
Venous and peripheral arterial vascular thrombotic events (ie, deep vein thrombosis and 
pulmonary  embolism) .
Congestive heart failure .
Cardiac arrhy thmia .
Syncope of a cardiovascular origin.
Severe /accelerated h ypertension leading to hospi[INVESTIGATOR_059] .
If the event is a nSAE , the procedures outlined in Section 12.3.2, Serious Adverse Events, should 
be followed. If the event is a nonserious AE, procedures outlined in the Trial Center File for 
nonserious AE s (as described a bove) should be followed.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_1204000] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All SAEs occurring during thestudymust be reported to the appropriate sponsor contact [CONTACT_184932] -site personnel within [ADDRESS_1204001] 
be completed and reviewed by a physician from the study  site, and transmitted to the sponsor 
within 24 hours. The initial and follow -up reports of a nSAE should be made by [CONTACT_6972] (fax).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
63
Approved , Date: [ADDRESS_1204002]'s participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as a nSAE . 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a subject's participation in a study  must be reported as anSAE , except hospi[INVESTIGATOR_111074]:
Hospi[INVESTIGATOR_863350](eg, social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
subject’s source documentation ). Note: Hospi[INVESTIGATOR_863351], and where the underly ing condition for which the hospi[INVESTIGATOR_863352] ,will not be considered SAE s. Any AE that results in a 
prolongation of the originally  planned hospi[INVESTIGATOR_300412] a new SAE .
For convenience ,the investigator may choose to hospi[INVESTIGATOR_184833].
The cause of death of a subject in a study  within [ADDRESS_1204003] be reported 
to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered SAE s 
and must be reported using the SAE Form. Any subject who becomes pregnant during the study  
must be promptly  withdrawn from the study  and discontinue further study  treatment.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
includ ed in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
64
Approved , Date: [ADDRESS_1204004] administration of 
study  agent(s) in subjects participating in this clinical study  must be reported by [CONTACT_41033] 9.6. Investigators are also advised that active TB is 
considered a reportable disease in most countries. These events are to be considered serious only 
if they  meet the definition of a nSAE .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HANDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its l abeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the spons or, and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_1204005] report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 12.3.2 , Serious Adverse 
Events). A sample of the suspected product should be maintained for further investigation if 
requested b y the sponsor .
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
14.1.1. Guselkumab
The guselkumab supplied for this study  is a sterile liquid for SC injection in a singl e-use PFS
assembled with the PFS-U. Each single -use PFS-U contains 100 mg (1 mL fill of liquid) 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
65
Approved , Date: 5 October 2017guselkumab in a 1 mL glass syringe with a 27 gauge, ½-inch fixed needle and a latex -free rigid 
needle shield . No preservatives are present. The guselkumab solution should be essentially  free 
of visible particulate matter. Guselkumab will be manufactured and provided under the 
responsibility  of the sponsor. Refer to the Investigator's Brochure for a list of excipi[INVESTIGATOR_840].
Placebo is supplied as a sterile liquid for SC injection at a fill volume of 1.0 mL in a single -use 
PFS assembled with the PFS-U. Each PFS-U contains 10 mM L-histidine, 8.5% (w/v)sucrose, 
and 0.055% (w/v) pol ysorbate 80 at pH 5.8.
14.1.2. Cosenty x (Secukinumab)
Commercial secukinumab (Cosent yx) will be supplied as an active comparator to the study sites. 
Details on secukinumab are available in the secukinumab (Cosent yx) package insert, and details 
regarding the secukinumab drug product for individual countries are available in the Site 
Investigational Product Procedures Manual.
14.2. Packaging
The investigational supplies will be uniquel y packaged to assure that they are appropriatel y 
managed throughout the supply  chain process .
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
14.4.1. Guselkumab
Guselkumab and placebo for guselkumab will be supplied to the study  sites. All guselkumab and 
placebo for guselkumab must be stored at controlled temperatures ranging from 36°F to46°F
(2°C to8°C) and protected from exposure to light. The sterile product does not contain 
preservatives and is designed for single use only. Protection from light is not required during 
dose preparation or administration of guselkumab.
Further details regarding the preparation and storage of guselkumab and placebo will be 
provided in the Site I nvestigational Product Procedures Manual.
14.4.2. Cosenty x (Secukinumab)
Cosenty x will be supplied to the sites. All Cosenty x must be stored in a refrigerator at 2ºC to 8ºC 
(36ºF to 46ºF). Keep the product in the original carton to protect from light until the time of use. 
Do not freeze. To avoid foaming do not shake. The sterile product does not contain preservatives 
and is designed for single use onl y. Before injection , remove Cosent yx prefilled sy ringe from the 
refrigerator and allow Cosenty x to reach room temperature (15 to 30 minutes) without removing 
the needle cap.
The removable cap of the Cosenty x PFS contains natural rubber latex and should not be handled 
by [CONTACT_863384]-sensitive individuals.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
66
Approved , Date: [ADDRESS_1204006] Cosenty x for particulate matter and discoloration prior to administration. 
Cosenty x injection is a clear to slightl y opalescent, colorless to slightly  yellow solution. Do not 
use if the liquid contains visible particles, is discolored or cloudy . Cosenty x does not contain 
preservatives; therefore, administer the PFS within [ADDRESS_1204007] be 
documented on the drug accountability  form. All study  drug will be stored and disposed of 
according to the sponsor's instructions. Study-site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appro priate 
environmental conditions. Unused study  drug must be available for verification by [CONTACT_456]'s 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study 
drug will be documented on the drug return form. When the study  site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Study  drug may not be relabeled or reassigned for use by 
[CONTACT_23837]. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator 'sBrochure for guselkumab.
Package Insert /Summary of Product Characteristics for secukinuma b.
Site Investigational P roduct Procedures M anual .
Laboratory  Manual .
IWRS Manual .
Electronic Data Capture ( eDC)Manual .
Electronic Device and User Manual .
Electronic Columbia- Suicide Severit y Rating Scale .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
67
Approved , Date: 5 October 2017Sample I CF.
Sample genetic research for ICF, as applicable .
ECG Manual .
Recruitment materials, as needed .
Biopsy  Manual (for biopsy  substudy  sites only ).
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to partici pate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential AEs ofthe study, and provide their consent voluntaril y will be enrolled.
The total blood volume to be collected is considered to be an acceptable amount of blood to be 
collected over this time period from the population in this study  based upon the standard of the 
American Red Cross (1 pi[INVESTIGATOR_11731]/473 mL of blood for donation) .
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
68
Approved , Date: 5 October 2017Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Informa tion regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after theIEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required locall y), the ICF, applicable 
recruiting materials, andsubject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICFmust 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component .
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to b e provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification i f a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
69
Approved , Date: 5 October 2017For all protocol amendments (excluding the ones that are purel y administrative, with no
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational ins titution) .
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/areused must be approved by [CONTACT_170510]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benef its, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that cho osing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease. Subjects will be told 
that alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally , they will be told that the investigator will maintain a subject 
identification register for the purposes of long-term follow up if needed and that their records 
may be accessed by [CONTACT_417645], to the extent permitted by [CONTACT_6983](s) or regulations. By 
[CONTACT_23842] .It also denotes that the subject agrees to 
allow his or her study  physician to recontact [CONTACT_66882] y evaluations, and subsequent disease -related treatments, if needed. The 
physician may also recontact [CONTACT_863385].
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by [CONTACT_19720]'s person ally dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Subjects will be asked for consent to provide optional samples for research (where local 
regulations permit). After informed consent for the study  is appropriatel y obtained, the subject 
will be asked to sign and personall y date a separate ICFindicating agreement to participate in the 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
70
Approved , Date: [ADDRESS_1204008] includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related moni toring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regula tions.
Exploratory  DNA and biomarker research is not conducted under standards appropriate for the 
return of data to subjects. I n addition, the sponsor cannot make decisions as to the significance of 
any findings resulting from exploratory  research. Theref ore, exploratory  research data will not be 
returned to subjects or investigators, unless required by [CONTACT_23844]. Privacy  and 
confidentiality  of data generated in the future on stored samples will be protected by [CONTACT_67828].
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand guselkumab and 
co-medications in the protocol, if applicable, to understand plaque -type psoriasis , to understand 
differential drug responders, and to develop tests/assays related to guselkumab and 
co-medications in the protocol, if applicable and plaque- type psoriasis. The research may begin 
at an y time during the study or the post- study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer toSection 10.3, Withdrawal From the Use of Samples in Future 
Research ).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
71
Approved , Date: [ADDRESS_1204009] not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to elimin ate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_307510] (s), which will beprovided as a separate
document . Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_233869]. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approv al/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol a nd amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applica ble, subject compensation programs. This approval must clearly  identify  the specific 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
72
Approved , Date: [ADDRESS_1204010] be signed (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IR B, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/op inion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financ ial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  [CONTACT_863386]:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and S creening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
73
Approved , Date: [ADDRESS_1204011] be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by [CONTACT_12695]; record of all AEs and follow -up of AEs; concomitant medication; drug 
receipt/dispensing/return records; study  drug administration information ; and date of study  
completion and reason for early discontinuation of study  drug or withdrawal from the study , if 
applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (o r equivalent document).
Investigator -completed efficacy  evaluations (IGA, PASI) and the subject -completed eC-SSRS 
will be recorded directl y into an electronic tablet device during the visit atthe study  site. These 
data will be considered electronic source documentation.
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
Referral letter from tre ating phy sician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are prepared and provided by  [CONTACT_66888].
All eCRF entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify  that all data entries in the eCRF are accurate 
and correct.
The study  data will be transcribed by [CONTACT_3449]-sitepersonnel from the source documents onto an 
electr onic eCRF ,if applicable. Study -specific data will be transmitted in a secure manner to the 
sponsor.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
74
Approved , Date: [ADDRESS_1204012]'s source docu ment s. Data must be entered into 
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale informat ion or other questionnaires) will be 
completed by [CONTACT_23856].
If necessary , queries will be generated in the eDC tool. If corrections to aneCRF are needed 
after the initial entry  into the eCRF , this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitorin g visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  and direct transmission of 
efficacy  and eC -SSRS data into the sponsor's data base. Written instructions will be provided for 
collection, handling, storag e, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRF for accuracy  and completeness during on-
site monitoring visits and after transmis sion to the sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compli ance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_764605] 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
75
Approved , Date: 5 October 2017agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval fro m the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compar e the data entered into the eCRF with the source documents
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) . At these visits, the monitor will compare 
data entered into the eCRF with the source documents (eg, hospi[INVESTIGATOR_307] /clinic/phy sician’s office 
medical records) ; a sample may be reviewed. The nature and location of all source documents 
will be identified to ensure that all sources of original data required to complete the eCRF are 
known to the sponsor and study -site personnel and are accessible for verification by [CONTACT_674757] -site contact. If electronic records are maintained at the study site, the method of 
verification must be discussed with the study -site personnel .
Direct access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the releva nt study -site personnel will be available, the source document swill 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site.
Central monitoring will take place for data identified by  [CONTACT_70467].
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The study  is considered completed with the last scheduled study  assessment shown in the Time 
and Events Schedule for the last subject participating in the study . The final data from the study
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
76
Approved , Date: 5 October 2017site will be sent to the sponsor (or designee) after completion of the final subject assessment at 
that study  site, in the time frame specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health a uthorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspec tion. Subject privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192].
Simi lar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  thesponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding guselkumab or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and any data, including genetic or exploratory  biomarker research data, 
generated as a result of this study , areconsidered confidential and remain the sole propert y of the 
sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study , and will not use it for other purposes without the 
sponsor's prior written consent.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
77
Approved , Date: 5 October 2017The investigator understands that the information developed in the study will be used by [CONTACT_863387], and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtaine d in the study .
The results of the study will be reported in a Clinical Study  Report (CSR) generated by [CONTACT_863388] . 
Recruitment performance or specific expertise related to the nature and the key assessment 
parameters of the study  will be used to determine a coordinating investigator . Results of genetic 
or exploratory  biomarker analy ses performed after the CSR has been issued will be reported in a 
separate report and will not require a revision of the CSR . Study  subject identifiers will not be 
used in publication o f results. Any  work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by [CONTACT_23868]) shall be the propert y of the sponsor as author and owner of 
copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after theprimary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
78
Approved , Date: 5 October 2017REFERENCES
1. Blauvet A, Lebw ohl M, Bissonnette R. IL-23/IL -17A dy sfunction phenotypes inform possible clinical effects 
from anti-IL-17A therapi[INVESTIGATOR_014] .J Invest Dermatol . 2015; 135(8):1946 -1953.
2. Bow es J, Orozco G, Flynn E, et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic 
arthritis. 70, no. 9 (2011): 1641 -1644.
3. Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the 
[LOCATION_002]. J Am Acad Dermatol. 2016;74(1):190 -192.
4. Duerr RH, Taylor KD, Brant SR, et al. A genome -wide association study identifies IL23R as an inflammatory 
bowel disease gene. Science .2006; 314(5804):1461 -1463.
5. Fredriksson T, Pettersson U. Severe psoriasis -oral therapy with a ne w retinoid. Dermatologica .
1978; 157:238 –244.
6. Langley RG, Elewski BE, Lebwohl M, et al; ERASURE Study Group; FIXTURE Study Group. Secukinumab 
in plaque psoriasis --results of tw o phase 3 trials. N Engl J Med. 2014; 371(4):326 -338. doi: 
10.1056/NEJMoa1314258.
7. Liu Y, Helms C, Liao W, et al. A genome- wide association study of psoriasis and psoriatic arthritis identifies 
new disease loci. PLoS Genet .2008 ;4(3) :e1000041.
8. Lowes MA, Bow cock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445(7130):866 -
873.
9. Lowes M A, Suarez -Farina M ,Krueger JG.Immunology of Psoriasis.. Ann Rev Immunol. 2014;32: 227 –255.
10. Mundt, JC, Greist, JH, Jefferson, JW, et al. Predict ion of suicidal behavior in clinical research by [CONTACT_356361]- Suicide Severity Rating Scale. J Clin 
Psych. 2013;74(9):887 -893.
11. Nair RP, Duffin KC, Helms C, et al. Genome -wide scan reveals as sociation of psoriasis with IL -23 and NF κB 
pathways. Nat Genet. 2009; 41(2):199 -204.
12. Ness -Schwickerath K, Jin C ,Morita, C. Cytokine requirements for the differentiation and e xpansion of IL -
17A-and IL -22-producing hunab V(gamma)2V(delta) 2 T cells. J. Imm un. 2010 ;184:7268 -7280.
13. O'Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev 
Rheumatol. 2011; 7(12):718 -732.
14. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in 
inflammation. Immunity .2008;28( 4):454 -467.
15. Posner, K, Brow n, GK, Stanley, B, et al. The Columbia -Suicide Severity Rating Scale: Initial validity and 
internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 
2011;168(12):1266 -1277.
16. Revicki DA, Willian MK, Menter A, Saurat J -H, Harnam N, Kaul M. Relationship between clinical tesponse to 
therapy and health -related quality of life outcomes in patients with moderate to severe plaque psoriasis . 
Derm atology. 2008; 216:260–270.
17. Strober B, Papp KA, Lebw ohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am 
Acad Dematol. 2016; 75(1):[ADDRESS_1204013] clear skin in the clinical setting. J Am Acad Dematol. 2014 ;70:633-641.
19. Tato CM, O'Shea JJ. Immunology: what does it mean to be just 17? Nature .2006; 441(7090):166 -168.
20. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinum ab in clearing skin of subjects w ith 
moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dematol. 
2015; 73(3):400 -409.
21. Viswanathan HN, Chau D, Milmont CF, et al. Total skin clearance results in improvements in health -related
quality of life and reduced symptom severity among patients with moderate to severe psoriasis. Journal of 
Derm atological Treatment. 2015 ;26(3):235-239.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
79
Approved , Date: 5 October 2017Attachment 1:Investigator ’sGlobal A ssessment
Induration (I) (averaged over all lesions; use the Nati onal Psoriasis Foundation Reference card 
for measurement)
0 = no evidence of plaque elevation
1 = minimal plaque elevation, = 0.25 mm
2 = mild plaque elevation, = 0.5 mm
3 = moderate plaque elevation, = 0.75 mm
4 = severe plaque elevation, > 1 mm
Erythema (E) (averaged over all lesions)
0 = no evidence of ery thema, hy perpi[INVESTIGATOR_417803]
1 = faint ery thema
2 = light red coloration
3 = moderate red coloration
4 = bright red coloration
Scaling (S) (averaged over all lesions)
0 = no evidence of sca ling
1 = minimal; occasional fine scale over less than 5% of the lesion
2 = mild; fine scale dominates
3 = moderate; coarse scale predominates
4 = severe; thick, scale predominates
Total Average = ( I + E + S) / 3
Investigator’s Global Assessment based upon above Total Average
0 = Cleared, except for residual discoloration
1 = Minimal - majority  of lesions have individual scores for I + E + S / 3 that averages 1
2 = Mild - majority  of lesions have individual scores for I + E + S / 3 that averages 2
3 = Moderate - majorit y of lesions have individual scores for I + E + S / 3 that averages 3
4 = Severe - majorit y of lesions have individual scores for I + E + S / 3 that averages 4
Note: Scores should be rounded to the nearest whole number. If total ≤ 1.49, score = 1; if total ≥
1.50, score = 2.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
80
Approved , Date: 5 October 2017Attachment 2:Psoriasis A rea and Severity Index
The Psoriasis Area and Severity Index (PASI) is a system used for assessing and grading the severity of 
psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 
to 72. The severity of the disease is calculated as follows.
In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower 
extremities, which account for 10%, 30%, 20%, and 40% of the total BSA, respectively. Each of these 
areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4.
The scoring system for the signs of the disease (erythema, induration, and scaling) are: 0 =none, 1 = 
slight, 2 = moderate, 3 = severe, and 4 = very severe.
The scale for estimating the area of involvement for psoriatic lesions is outlined below.
0 = no involvement
1 = 1% to 9% involvement
2 = 10% to 29% involvement
3 = 30% to 49% involvement
4 = 50% to 69% involvement
5 = 70% to 89% involvement
6 = 90% to 100% involvement
To help with the area assessments, the following conventions should be noted:
a. The neck is considered part of the head
b. The axillae and groin are part of the trunk
c. The buttocks are part of the lower extremities
The PASI formula is:
PASI = 0.1 (Eh + Ih + Sh) Ah + 0.3 (Et + It + St) At + 0.2 (Eu + Iu + Su) Au + 0.4 (El + Il + Sl) Al
Where E = erythema, I = induration, S = scaling, A = area,
h = head, t = trunk, u = upper extremities, and l = lower extremities
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
81
Approved , Date: 5 October 2017Attachment 3:QuantiFERON®-TB Gold Testing
The QuantiFERON®-TB Gold test is one of the interferon -(IFN -) based blood assays for TB screening (Cellestis, 
2009). It utilizes the recently identified M.tuberculosis -specific antigens ESAT -[ADDRESS_1204014] 
format, as well as TB7.7 (p4) in the In-Tube format, to detect in vitro cell-mediated immune responses in infected 
individuals. The QuantiFERON®-TB Gold assay measures the amount of IFN -produced by [CONTACT_41056] T -cells when 
stimulated with the synthetic M. tuberculosis -specific antigens. In M. tuberculosis -infected persons, sensitized 
Tlymp hocytes will secrete IFN -in response to stimulation with the M. tuberculosis -specific antigens and, thus, the 
QuantiFERON®-TB Gold test should be positive. Because the antigens used in the test are specific to M. 
tuberculosis and not found in BCG, the test is not confounded by [CONTACT_14400], unlike the tuberculin skin test. 
How ever, there is some cross -reactivity with the [ADDRESS_1204015] could be the result of infection with one of these 3 species of Mycobacterium, in the 
absence of M. tuberculosis infection.
In a study of the QuantiFERON®-TB Gold test (standard format) in subjects with active TB, sensitivity has been 
shown to be approximately 89% (Mori et al, 2004). Specificity of the test in healthy BCG -vaccinated individuals has 
been demonstrated to be more than 98%. In contrast, the sensitivity and specificity of the tuberculin skin test was 
noted to be only about 66% and 35% in a study of Japanese patients with active TB and healthy BCG -vaccinated 
young adults, respectively. How ever, sensitivity and specificity of the tuberculin skin test depend on the population 
being studied, and the tuberculin skin test performs best in healthy young adults who have not been BCG -
vaccinated.
Data from alimited number of published studies examining the performance of the QuantiFERON®-TB Gold assay 
in immunosuppressed populations suggest that the sensitivity of the QuantiFERON®-TB Gold test is better than the 
tuberculin skin test even in immunosuppressed patients (Ferrara et al, 2005; Kobashi et al, 2007; Matulis et al, 
2008). The ability of IFN --based tests to detect latent infection has been more difficult to study due to the lack of a 
gold standard diagnostic test; however, several TB outbreak studies have demonstrated that the tests correlated 
better than the tuberculin skin test with the degree of exposure that contacts had to the index TB case (Brock et al, 
2004; Ewer et al, 2003). In addition, TB contact [CONTACT_41057] a positive 
QuantiFERON®-TB Gold test result and were not treated for latent TB infection were much more likely to develop 
active TB during longitudinal follow -up than those who had a positive tuberculin skin test and a negative 
QuantiFERON®-TB Gold tes t result (Higuchi et al, 2007; Diel et al, 2008).
Although the performance of the new IFN--based blood tests for active or latent M.tuberculosis infection have not 
been well validated in the immunosuppressed population, experts believe these new tests will be at least as, if not 
more, sensitive, and definitely more specific, than the tuberculin skin test (Barnes, 2004; personal communication, 
April, [ADDRESS_1204016]).
Performing the QuantiFERON®-TB Gold Test
The QuantiFERON®-TB Gold test In-Tube format will be provided for this study. The In-Tube format contains 1 
additional M. tuberculosis -specific antigen, TB7.7 (p4), which is thought to increase the specificity of the test.
To perform  the test using the In-Tube form at, blood is drawn through standard venipuncture into supplied tubes that 
already contain the M. tuberculosis -specific antigens. Approximately [ADDRESS_1204017], each 
requiring 1mL of blood. One tube contains the M. tuberculosis -specific antigens, while the remaining tubes contain 
positive and negative control reagents. Thorough mixing of the blood with the antigens is necessary prior to 
incubation. The blood is then incubated for 16 to 24 hours at37C, after which tubes are centrifuged for 
approximately 15 minutes at 2000 to 3000 g. Follow ing centrifugation, plasm a is harvested from each tube, frozen, 
and shipped on dry ice to the laboratory. The laboratory will perform an ELISA to quantify the amount of IFN-
present in the plasma using spectrophotometry and computer software analysis.
The laboratory will analyze and report results for each subject, and sites will be informed of the results. Subjects 
who have an indeterminate result should have th e test repeated.
Adherence to Local Guidelines
Local country guidelines for immunocompromised patients should be consulted for acceptable antituberculous 
treatment regimens for latent TB. If no local country guidelines for immunocompromised patients exist, US 
guidelines must be follow ed.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
82
Approved , Date: 5 October 2017In countries in which the QuantiFERON® -TB Gold test is not considered approved/registered, a tuberculin skin test 
is additionally required.
References
Barnes PF. Diagnosing latent tuberculosis infection: Turning glitter to gold [editorial]. Amer J Respir Crit Care 
Med. 2004;170:[ADDRESS_1204018] in 
tuberculosis con tacts. Am J Respir Crit Care Med. 2004;170:65 -69.
Cellestis. QuantiFERON -TB Gold clinicians guide and QuantiFERON -TB Gold In -Tube Method package insert. 
Downloaded from www.cellestis.com, February 2009.
Diel R, Loddenkemper R, Meywald -Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN -
assay for the development of active tuberculosis disease after recent infection with mycobacterium tuberculosis. Am 
J Respir Crit Care Med . 2008;177:[ADDRESS_1204019] for diagnosis of 
Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003;361:1168 -73.
Ferrara G, Losi M, Meacci M, et al. Routine hospi[INVESTIGATOR_40964] a new commercial whole blood in terferon -assay for 
the diagnosis of tuberculosis infection. Am J Respir Crit Care Med . 2005; 172:631 -635.
Higuchi K, Nobuyuki H, Mori T, Sekiya Y. Use of QuantiFERON -TB Gold to investigate tuberculosis contacts in a 
high school. Respi[INVESTIGATOR_16921] . 2007;12:[ADDRESS_1204020] for immunocompromised 
patients. Eur Respir J . 2007; 30:945 -950.
Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients wi th 
autoimmune diseases: performance of a Mycobacterium tuberculosis antigen -specific interferon assay. Rheum  
Dis. 2008;67:84 -90.
Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: An interferon --based assay 
using new antigens. Am J Respir Crit Care Med. 2004;170:59 -64.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
83
Approved , Date: 5 October 2017Attachment 4:Tuberculin Skin Testing
Administering the Mantoux Tuberculin Skin Test
The Mantoux tuberculin skin test (CDC, 2000) is the standard method of identifying persons infected with 
Mycobacterium tuberculosis . Multiple puncture tests (Tine and Heaf) should not be used to determine whether a 
person is infected because the amount of tuberculin injected intradermally cannot be precisely controlled. Tuber culin 
skin testing is both safe and reliable throughout the course of pregnancy. The Mantoux tuberculin test is performed 
by [CONTACT_269329] 0.1mL of tuberculin into the inner surface of the forearm. The test must be 
performed with tuberculin that has at least the same strength as either 5tuberculin units (TU) of standard purified 
protein derivative ([COMPANY_003]) -S or 2TU of [COMPANY_003]-RT23, Statens Seruminstitut, as recommended by [CONTACT_67848]. [COMPANY_003] strengths of 1TU or 250TU are not acceptable (Menzies, 2000). Using a disposable tuberculin 
syringe with the needle bevel facing upward, the injection should be made just beneath the surface of the skin. This 
should produce a discrete, pale elevation of the skin (a wheal) 6mm to 10mmin diameter. To prevent needle -stick 
injuries, needles should not be recapped, purposely bent or broken, removed from disposable syringes, or otherw ise 
manipulated by [CONTACT_35681]. After they are used, disposable needles and syringes should be placed in puncture -resistant 
containers for disposal. Institutional guidelines regarding universal precautions for infection control (eg, the use of 
gloves) should be follow ed. A trained health care worker, preferably the investigator, should read the reaction to the 
Mantoux test [ADDRESS_1204021], tuberculin testing 
should be repeated. The area of induration (palpable raised hardened area) around the site of injection is the reaction 
to tuberculin. For standardization, the diameter of the induration should be measured transversely (perpendicular) to 
the long axis of the forearm. Erythem a (redness) should not be measured. All reactions should be recorded in 
millimeters, even those classified as negative.
Interpreting the Tuberc ulin Skin Test Results
In the US and many other countries, the most conservative definition of positivity for the tuberculin skin test is 
reserved for immunocompromised patients, and this definition is to be applied in this study to maximize the 
likelihood of detecting latent TB, even though the subjects may not be immunocompromised at baseline.
In the US and Canada, an induration of 5mm or greater in response to the intradermal tuberculin skin test is 
considered to be a positive result and evidence for ei ther latent or active TB.
In countries outside the US and Canada, country -specific guidelines for immunocomprom ised patients should be 
consulted for the interpretation of tuberculin skin test results. If no local country guidelines for 
immunocompromised patients exist, US guidelines must be follow ed.
Treatment of Latent Tuberculosis
Local country guidelines for immunocompromised patients should be consulted for acceptable antituberculous 
treatment regimens for latent TB. If no local country guidelines for immunocompromised patients exist, US 
guidelines must be follow ed.
References
Centers for Disease Control and Prevention. Core curricul um on tuberculosis: What the clinician should know 
(Fourth Edition). Atlanta, GA: Department of Health and Human Services; Centers for Disease Control and 
Prevention; National Center for HIV, STD, and TB Prevention; Division of Tuberculosis Elimination; 20 00:25 -86.
Menzies RI. Tuberculin skin testing. In: Reichman LB, Hershfield ES (eds). Tuberculosis, a comprehensive 
international approach . 2nd ed. New  York, NY: Marcel Dekker, Inc; 2000:279 -322.
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
84
Approved , Date: 5 October 2017Attachment 5:Hepatitis B Virus (HBV ) Screening With HBV DNA  Testing
Subjects must undergo screening for hepatitis B virus (HBV). At a minimum, this includes 
testing for HBsAg (HBV surface antigen), anti-HBs (HBV surface antibody ), and anti-HBc total 
(HBV core antibod y total):
Subjects who test negative for all HBV screening tests (ie, HBsAg -, anti-HBc-, and 
anti-HBs-) are eligible for this study .
Subjects who test negative for surface antigen (HBsAg -) and test positive for core 
antibody  (anti -HBc+) andsurface antibod y (anti -HBs+) are eligible for this study .
Subjects who test positive only for surface antibody (anti-HBs+) are eligible for this 
study .
Subjects who test positive for surface antigen (HBsAg+) are NOT eligible for this study , 
regardless of the results of other hepatitis B tests.
Subjects who test positive only for core antibody (anti-HBc+) must undergo further 
testing for the presence of hepatitis B virus deoxy ribonucleic acid (HBV DNA test). If 
the HBV DNA test is positive , the subject is NOT eligible for this study . If the HBV 
DNA test is negative , the subject is eligible for this study . In the event the HBV DNA 
test cannot be performed, the subject is NOT eligible for this study .
For subjects who are not eligible for this study due to HBV test results , consultation with a 
physician with expertise in the treatment of hepatitis B virus infection is recommended.
Eligibility based on hepatitis B virus test results
Hepatitis B test result
ActionHepatitis B 
surface antigen
(HBsAg)Hepatitis B 
surface antibody
(anti -HBs)Hepatitis B core 
antibody
(anti -HBc total)
Include— — —
— + —
— + +
Exclude + —or+ —or+
Require testing for presence 
HBV DNA*— — +
* If HBV DNA is detectable, exclude from the clinical study. If HBV DNA testing cannot be 
performed, or there is evidence of chronic liver disease, exclude from the clinical study. 
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
85
Approved , Date: 5 October 2017Attachment 6:Anticipated Events
Anticipated Event
An anticipated event is an AE(serious or non-serious) that commonly occurs as a consequence of the 
underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the event of psoriasis will be c onsidered anticipated event .
Reporting of Anticipated Events
All AEs will be recorded in the eCRF regardless of whether considered to be anticipated events and will 
be reported to the sponsor asdescribed in Section 12.3.1 , All Adverse Events . Any anticipated event that 
meets SAE criteria will be reported to the sponsor as described in Section 12.3.2, Serious Adverse Events. 
These anticipated events are exempt from expedited reporting as individual single cases to Health 
Authorities. However ,if based on an aggregate review, it isdetermined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform review s of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis ofanticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
CNTO 1959 (guselkumab) Clinical Protocol CNTO1959PSO3009 Amendment 1
86
Approved , Date: 5 October 2017INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]